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SUMMARY
Advances in high-throughput genomic and proteomic technology have led to
a growing interest in cancer biomarkers. These biomarkers can potentially improve
the accuracy of cancer subtype prediction and subsequently, the success of therapy.
However, identification of statistically and biologically relevant biomarkers from high-
throughput data can be unreliable due to the nature of the data-e.g., high technical
variability, small sample size, and high dimension size. Due to the lack of available
training samples, data-driven machine learning methods are often insufficient without
the support of knowledge-based algorithms. We research and investigate the benefits
of using knowledge-based algorithms to solve clinical prediction problems. Because
we are interested in identifying biomarkers that are also feasible in clinical prediction
models, we focus on two analytical components: feature selection and predictive
model selection. In addition to data variance, we must also consider the variance
of analytical methods. There are many existing feature selection algorithms, each
of which may produce different results. Moreover, it is not trivial to identify model
parameters that maximize the sensitivity and specificity of clinical prediction. Thus,
we introduce a method that uses independently validated biological knowledge to
reduce the space of relevant feature selection algorithms and to improve the reliability
of clinical predictors.
Biologically relevant feature selection algorithms are those that favor indepen-
dently validated biomarkers. We show that guiding feature ranking algorithm and
parameter selection using these biomarkers improves the efficiency of detecting new
xiii
biomarkers that are also likely to validate. Furthermore, the algorithm selection pro-
cess iteratively evolves as it learns and incorporates new biomarkers into the knowl-
edge set. Using both maximum likelihood and maximum a posteriori approaches,
we show that the choice of an optimal or biologically relevant method changes in the
presence of knowledge feedback. The clinical utility of biomarkers depends on their
feasibility in clinical prediction applications. Thus, in a similar approach as–and in
collaboration with–the FDA Microarray Quality Control (MAQC) Consortium, we
examine several microarray datasets to assess the effect of knowledge-guided feature
selection on prediction accuracy. The microarray datasets in our study vary in sam-
ple size and clinical focus. For each clinical focus–renal cancer, prostate cancer, and
breast cancer–we build and test classification models using independent training and
testing datasets in order to reduce prediction bias. Results of these experiments in-
dicate that knowledge-guided feature selection improves clinical prediction. Finally,
one of the primary obstacles in translating research to clinical applications is the in-
accessibility of bioinformatics applications to the general community of clinicians and
biologists. Therefore, we implement several functions of the knowledge-based frame-
work as a web-based and user-friendly application called omniBiomarker. We develop
functions of omniBiomarker according to standards of the NCI Cancer BioInformatics




Traditional medical techniques are subjective, especially for clinical problems such
as cancer subtype classification. This subjectivity often limits the effectiveness of
therapy. For example, cancers with similar morphologic characteristics may behave
very differently under similar treatment conditions [50]. Furthermore, some cancer
subtypes are more likely to recur after completion of treatment [119, 96]. Thus,
recent diagnostic research focusing on these issues involves identification of diag-
nostic markers–called biomarkers–that have the potential to increase accuracy and
remove subjectivity from cancer diagnosis. This relatively new approach to medical
diagnostics has become possible with the advent of high-throughput technology for
measuring biomolecular expression–e.g., genes, proteins, and other biomolecules. Es-
sentially, this technology has allowed us to take snapshots of the functional state of
a biological process. From these snapshots, which typically contain large quantities
of data, we can identify the components that are most correlated with clinical symp-
toms, and then assemble the components into a cohesive story that may explain the
internal biological mechanisms of a disease. Most importantly, we can use some of
these components as clinical predictors of disease state.
However, the analytical procedure for high-throughput data is not without pitfalls.
We call this analytical procedure the biomarker identification pipeline. It consists of
several steps with multiple possible solutions at each step: 1) data acquisition, 2)
quality control and normalization, 3) feature selection, 4) validation and biological
interpretation, and 5) clinical prediction (Figure 1). From a purely data-driven per-










































Figure 1: Biomarker Identification Pipeline. The translational bioinformatics
pipeline includes several steps that guide us from a clinical problem to a clinical so-
lution. The first step involves acquisition of relevant data, normally in the form of
large quantities of genetic or proteomic expression data and associated patient his-
tory. Before analyzing the data to identify differentially expressed biomarkers, we
must assess and improve the quality of the data by removing technical artifacts and
combining multiple datasets to improve statistical relevance. Stage two of data pro-
cessing involves knowledge-guided identification of relevant, differentially expressed
biomarkers. We obtain the knowledge from external sources as well as through iter-
ative feedback to improve the efficiency of biomarker identification. Finally, before
using biomarkers in the feedback process or in a clinical application, we must vali-
date their functional relevance by directly assessing expression with alternate assay
technologies such as IHC or qRT-PCR.
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Figure 2: Curse of Dimensionality. The sample space within a unit interval
increases exponentially as dimension increases. This is problematic for learning algo-
rithms because a larger number of samples is required to adequately cover the sample
space and accurately represent the population.
analysis parameters due to the nature of the data (small sample size relative to high
dimension, known as the “curse of dimensionality” problem) [134, 92]. Furthermore,
because of the multiple solutions at each step, there are many possible paths in the
pipeline, each of which can produce a different result. As such, it is generally not
reproducible. We cannot expect a single path to perform well for all clinical scenarios
[41]. Rather, we should use specific analysis parameters for each clinical problem.
Aside from exhaustively searching every possible analytical path, how do we deter-
mine the best parameters for a particular clinical scenario? We address this problem
by describing methods to integrate information and increase the amount of available
data for solving clinical problems. In addition to combining data from heterogeneous
sources, we introduce a method that uses prior biological knowledge to choose an
analytical path in the biomarker identification pipeline. Specifically, we focus on the
following steps in the pipeline: feature selection, biomarker validation, and estimation
of prediction accuracy.
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In order to better convey the difficulty of high-throughput data analysis, we de-
scribe the “curse of dimensionality” problem. This problem is most apparent in the
prediction component of the pipeline, which is a classic pattern recognition problem.
Typically, we train a prediction rule from a finite number of input samples in order to
classify future samples–in this case, microarray samples, which are the most common
high-throughput data platform. The more thoroughly the input samples cover the
space of all possible samples–i.e., the more samples available–the more accurately the
prediction rule will be able to classify future samples drawn from the same popula-
tion. Clinical prediction from microarray samples is problematic for two previously
mentioned reasons: small sample size and large sample dimension. Each microarray
sample contains thousands of genes and clinical microarray samples are difficult to ob-
tain in sufficiently large quantities to adequately represent the population. Although
the availability and cost of microarray samples has improved, we must consider this
growth with respect to the dimension size of each sample. The size of the input space
increases exponentially when the number of dimensions in each sample increases. For
example, consider a one-dimensional interval of unit length (Figure 2). We can sam-
ple at least five points from this space such that the points are evenly spaced at a
distance of no greater than 0.2 from adjacent points. If we increase the dimension of
this space to two–a square–the minimum number of evenly spaced samples required
to cover the space increases to 25. At 10 dimensions, this number increases to 510.
Thus, as the dimension size increases, we need more samples to adequately represent
the population. Microarrays are an extreme case. With a limited sample of the pop-
ulation, resulting clinical prediction rules will likely over-fit to a small fraction of the
population. Consequently, these prediction rules will be unable to generalize to the
population as a whole, resulting in poor prediction performance. Bioinformaticians
handle this problem by reducing the dimensionality of the data, usually by removing
or selecting features based on their potential predictive ability. However, the curse of
4
dimensionality also affects feature selection from high-throughput data.
Every step in the biomarker identification pipeline affects the final result: accu-
racy of the clinical prediction rule. However, assuming that the acquired data is of
reasonable quality, the feature selection step is arguably the most important. The
features not only affect the complexity of the resulting classifier, but they also provide
us with some clues about the underlying biology of the clinical problem. Therefore, it
is not surprising that feature selection is one of the more difficult steps of the pipeline.
Feature selection algorithms are optimization problems that search for the best set of
genes–in the case of microarray data–with the highest potential for accurate predic-
tion. Because gene expression is not independent, feature selection algorithms must
identify groups of genes that act in concert [150]. Here, we must again tackle the
curse of dimensionality problem, this time in the context of optimization. The space
of possible gene combinations increases exponentially as the number of dimensions
increases. For example, consider the problem of searching for a single gene from a
set of N total genes. Here, we need only evaluate N genes to find the best pre-
dictor. But suppose we are interested in a pair of genes. In this case, we need to
evaluate N !/[2!(N − 2)!] total gene pairs. In the case of choosing K genes out of N
total, the number of unique groups grows exponentially to N !/[K!(N − K)!]. K is
also unknown, although some studies have tried to determine the optimal number of
genes for maximizing prediction accuracy [57]. Indeed, there is no existing algorithm
that can find the true optimal set of genes from a typical gene expression dataset.
The problem is simply too computationally intractable. As such, there are many
algorithms that approximate the optimal solution from a reduced search space [31].
However, these approximate gene lists are highly variable and depend on both the
algorithm and the data. Fortunately, we may still be able to solve this problem by
using knowledge-based methods.
Consider the problem of guessing a shape given only four points randomly sampled
5





Planar Closed Smooth Uniform
Curve






























































Biomarker A Biomarker B Biomarker C Biomarker D
Data
































Knowledge-Based Methods Reduce Search Spaces
Figure 3: Knowledge-Based Methods. A simple example of search space reduc-
tion is guessing a shape given only a few data points (top). As information about
the geometric shape is introduced, the number possible solutions shrinks. Eventually
the true shape emerges as the only solution. Likewise, the biomarker search space is
large due to the variety of available feature selection algorithms, each of which pro-
duces a different list of candidate biomarkers (bottom). As information about true
biomarkers is introduced, the number of valid feature selection algorithms reduces.
The reduced population of algorithms includes those that can consistently identify
the known biomarkers.
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from the surface of the shape (Figure 3). This is impossible because there are infinite
possibilities. However, if we can obtain additional clues about the shape, we can begin
to narrow the possibilities. For example, if we know that these four points exist on
a single plane, then we can exclude three dimensional shapes. If we are told that
the shape is closed and smoothly curved, we can reduce the possibilities even further.
Finally, if we know that the curvature of the shape is uniform, then there is only one
possibility: a circle. Similarly, given a set of microarray samples drawn randomly
from a population of patients, there are an exponential number of potential gene
lists, varying due to the many algorithms as well as patient heterogeneity. However,
if we know that relevant feature selection algorithms should favor specific biomarkers,
then we can narrow the list of algorithms and subsequently, the number of potential
solutions.
The integration of knowledge in the biomarker identification pipeline is essential
for overcoming the curse of dimensionality, stabilizing the variability of feature selec-
tion and prediction results, and increasing the overall reproducibility of the process.
As indicated in (Figure 1), we can obtain prior knowledge from external sources
or through a feedback mechanism after the validation step. Each of the following
chapters represents work that has been published or is in preparation for publication
in peer reviewed journals or conference proceedings. In Chapter 2, we introduce
previous work in the areas of microarray technology and existing analytical meth-
ods. Particularly, we review several studies that have relied on high-throughput gene
expression technology to better understand biological mechanisms of disease. Be-
cause high-throughput technology is not without hazards, we review several studies
that examine these hazards, primarily pertaining to statistical quality of the data
and resulting analytical challenges. Portions of this chapter have been summarized
in an article that reviews knowledge-based bioinformatics and applications of these
methods to biomarker identification and cancer nanotechnology [105]. As we have
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noted, one of the primary problems in high-throughput data analysis is the lack of
samples. Chapter 3 introduces a method to combine heterogeneous microarray data
in order to improve the statistical significance of subsequent analyses [104]. Chapter
4 introduces a method to improve the biological relevance of feature selection from
high-throughput data and, at the same time, increase reproducibility of the analytical
results [106]. Chapter 5 is a large scale application of these ideas into a framework
of clinical prediction. Here, we examine the feasibility of microarrays for clinical pre-
diction. We focus primarily on the notion of biological relevance: does the biological
relevance of analytical methods such as feature selection correlate to higher predictive
performance? The work in Chapter 5 was inspired by our collaboration with the
FDA which produced several manuscripts currently under review [127, 102, 68]. Fi-
nally, in Chapter 6, we introduce a translational bioinformatics software application
that aims to deliver knowledge integration technology to a wider audience of clinicians
and biologists. This software application, called omniBiomarker, is currently under




The primary clinical motivation for using high-throughput data is disease therapeu-
tics. Many studies have used microarray technology to identify differentially expressed
disease biomarkers using clinically derived patient data. These biomarkers serve as
diagnostic and prognostic indicators that subsequently determine therapeutic choices.
This chapter reviews the literature focusing primarily on applications of microarray
technology to cancer. Specifically, we identify studies that search for differentially
expressed genes with the aim of cancer prediction or clinical subtype discovery. The
clinical community uses a very diverse set of analytical techniques. As such, we
also review techniques that correlate to steps in the biomarker identification pipeline:
quality assessment, feature selection, data combination, and prediction.
For the reasons mentioned in the previous chapter, bioinformatics techniques have
increasingly gravitated to knowledge-driven techniques. Thus, as an introduction to
our own techniques, we also review recent developments in knowledge-based bioin-
formatics. Finally, because the use of bioinformatics in cancer applications is an
interdisciplinary endeavor, we review the many attempts to deliver bioinformatics
algorithms to the broader community of clinicians and biologists through software
applications.
2.1 Identifying Cancer Biomarkers Using Microarray Tech-
nology
The effectiveness of cancer treatment depends not only on early detection, but also on
accurate determination of the best therapeutic regimen. Pathologists examine mor-
phologic characteristics of cancer specimens to determine the subtype or stage of the
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disease. Physicians then select an appropriate course of treatment based on this in-
formation. The goal is to treat a patient’s cancer with minimally invasive procedures
while maximizing the patient’s comfort and chances for survival. Early detection
markers for some cancers have been successful while others are still under investiga-
tion. For example, prostate specific antigen (PSA) screening has improved the early
detection of prostate cancer [133]. Some studies have also identified markers able to
detect ovarian and breast cancer at early stages [130, 129, 49]. However, tailoring
treatment to individual patients has been much more difficult. As a result, treat-
ment is not always minimal and some patients relapse. For example, chemotherapy
and hormonal treatment can prevent breast cancer metastasis, but these treatments
are not always necessary [143, 16]. Furthermore, of all men who elect surgery after
detecting prostate cancer at an early stage, many are low risk and did not require
the surgery while almost one third relapse [133]. Some cancers, such as those of the
kidney, are very heterogeneous and include several histopathological subtypes with
distinct clinical and cytogenetic features [34]. Consequently, malignant renal cancers
are often difficult to treat, as clinical behavior is hard to predict [80]. These difficulties
in tailoring treatment to individual patients are due to the limitations in classifying
cancers based on morphologic characteristics and to the lack of accurate biomarkers
with high correlation to clinical outcomes.
Cancers with similar morphologic characteristics may behave very differently de-
spite similar treatment conditions [50]. In order to improve the prediction of clinical
outcomes, medical scientists have searched for other aspects of cancer not readily
apparent during morphologic inspection. Naturally, because cancer is the result of
genetic mutations, therapeutic research has primarily focused on molecular differ-
ences between clinically relevant subtypes. Engineers have developed technology for
quickly quantifying molecular expression and biologists have used this technology
(e.g. microarrays and mass spectrometry) to generate large quantities of clinical data
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[133, 143, 19, 124, 67, 81, 144, 116, 148]. Although these technologies produce data
faster than the rate at which we can thoroughly analyze and interpret them, biologists
have still identified many candidate biomarkers. Singh et al. obtained a large number
of prostate cancer microarray samples consisting of several histologic and clinical sub-
types. They were able to identify markers correlated with Gleason score (a measure of
the cancer’s stage, or level of severity) and markers that predict patient outcome fol-
lowing prostatectomy (removal of the prostate). However, the number of samples with
available clinical outcome data was relatively small and the authors did not test the
predictive performance of these markers using independent data [133]. Chandran et
al. used similar microarray samples to identify differential markers for distinguishing
two histologic classes of prostate cancer from normal tissue. Their study examined the
heterogeneity of prostate cancer and the effects of cancers on adjacent normal tissue
[19]. Varambally et al. used both proteomic and genomic assays to identify markers
for metastatic prostate cancer. They found protein markers with high correlation to
mRNA expression for predicting clinical outcome [144]. van’t Veer et al. identified a
panel of gene expression signatures that predicted metastasis after diagnosis of breast
cancer [143]. Liu et al. identified a 186-gene invasiveness gene signature (IGS) that
predicted metastasis and survival in breast cancer patients. They showed that this
gene signature was applicable to other types of cancer as well [81]. Schuetz et al.
examined microarray gene expression data for several renal tumor subtypes. They
identified many genes up-regulated for specific tumor subtypes compared to all other
samples. They verified some markers using qRT-PCR (quantitative Reverse Tran-
scription Polymerase Chain Reaction, an RNA amplification technique used to verify
gene expression [142]) and IHC (immunohistochemistry, a method for quantifying and
localizing proteins in a tissue sample using fluorescent antibodies [27]) [124]. Jones et
al. identified biomarkers for similar renal tumor subtypes in addition to a metastatic
subtype using a larger microarray dataset [67]. In both renal tumor studies, markers
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for distinguishing chromophobe (CHR) and oncocytoma (ONC) subtypes were dif-
ficult to identify because of histologic similarity between samples and small sample
size. Rohan et al. specifically addressed this issue and identified biomarkers to dis-
tinguish CHR and ONC renal tumor subtypes [116]. High-throughput genomic and
proteomic technology have improved biomarker identification for predicting cancer
subtype and clinical outcome. However, concerns regarding technology and protocol
standardization, data quality, data analysis methods prevent widespread use of this
technology in clinical settings [45].
2.2 Assessing the Quality of Microarray Data
Although many of the previously cited works have successfully used microarrays,
this technology is still subject to many technical issues. These issues include mi-
croarray quality, sample size, and feature size. Despite a major concern for the
quality of high-throughput microarray technology, recent studies have shown that
microarray technology is reproducible across laboratories and platforms [126]. For
example, Canales et al. compared five microarray platforms to three quantitative,
low-throughput, gene expression technologies, including TaqMan, standardized qRT-
PCR, and QuantiGene assays [17]. They found that all platforms generally agree
with quantitative results with the exception of a few genes due to weak expression
or differences in probe sequence. Furthermore, Patterson et al. compared one- and
two-color microarray platforms in terms of reproducibility, sensitivity, specificity, and
accuracy and found that these platforms are identical [103]. Two-color microarray
data needs special consideration when assessing data quality. Several software pack-
ages exist for two-color microarray data preprocessing, including arrayMagic [14]. On
the other hand, statistical artifacts in microarray data sometimes appear as spatially
correlated regions on arrays with abnormal hybridization. Specifically for Affymetrix
arrays, some algorithms, such as RMA Express, have been designed to compute gene
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expression and to visualize spatial artifacts [7, 62, 79, 135]. caCORRECT identifies
spatial artifacts with image processing algorithms and reduces their effect on gene
expression estimation using a modified quantile normalization method [137]. caCOR-
RECT also assigns quality scores to microarray chips, allowing us to remove samples
that are below a specified quality threshold. Similarly, the quality of microarray
hybridization experiments can be assessed as deviations of gene expression distribu-
tions from uniformity [12]. Several methods exist for normalization of microarray
data. These methods greatly affect downstream differential expression analysis and
should be carefully applied [54, 56, 63, 125]. Some of these normalization methods
address limitations in microarray design that introduce unwanted data correlations
[70]. Despite the general reproducibility of microarrays and the available software for
detecting and correcting statistical artifacts, the detection of differentially expressed
biomarkers is still difficult when data sample size is small and feature size is high.
Furthermore, statistical artifacts tend to be enhanced when sample size is small, re-
sulting in biased biomarker detection. Bioinformaticians have designed many feature
selection algorithms to specifically handle these problems.
2.3 Feature Selection and Gene Ranking Methods
Feature selection algorithms generally fall into two categories: filter and wrapper
methods [151, 61]. Filter methods, e.g., fold-change, signal to noise ratio, and vari-
ants of the t-test, rank genes by computing a score representing the degree of differ-
ential expression. Many studies have explored both parametric and non-parametric
filtering methods. Fold-change was the method of choice in many early biological
studies involving microarrays. Later research used parametric statistical tests such
as the t-test, which estimates Gaussian parameters for each class and computes the
significance of differential expression as a measure of error probability. However, the
statistical soundness of such simple methods is questionable, as these methods require
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strict and unrealistic assumptions about the data distributions. The problem with the
t-test, specifically, is the assumption of normality, which is not always true for gene
expression data [140]. In situations where data are not normally distributed, non-
parametric methods are more appropriate and can improve the results of biomarker
detection. For example, Troyanskaya et al. compared the standard t-test to a non-
parametric t-test that computes p-values using several thousand data permutations
[140]. They also examined the non-parametric Wilcoxon rank sum test, which ranks
biomolecule expression values and compares the mean rank between classes. Signifi-
cance analysis of microarrays (SAM), developed by Tusher et al., is a modified t-test
that also uses permutations to estimate p-values and selects biomolecules after adjust-
ing for the false discovery rate (FDR) [141]. Despite the success of filtering methods,
these methods are still lacking when applied to problems involving multi-dimensional
or non-linearly expressed genes. To address this, Lu et al. used Hotelling’s T 2 test, a
generalized multi-dimensional t-test, and identified differentially expressed gene com-
binations [84]. Biomarkers identified with filter methods are not necessarily accurate
classifiers [151]. Thus, much focus has turned to developing feature selection methods
that are also accurate estimators of classification performance.
Wrapper methods combine feature selection and classification by ranking genes
based on estimated classification accuracy [61, 151]. Because the primary applica-
tion of biomarker identification is to classify future samples, we place emphasis on
wrapper methods. Ranking genes based on classification accuracy better ensures the
performance of identified biomarkers in diagnostic applications. Wrapper methods
usually involve training a classifier with a finite set of labeled samples and testing the
classifier by predicting the class labels of an independent set of samples. The results
of testing are normally used as a ranking metric. In contrast to filter methods, wrap-
per methods are easily applied to multi-dimensional and non-linear data because of
the variety of available classifiers.
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The major obstacles for wrapper methods are model selection and sample size.
By carefully addressing these issues, we can avoid incorrectly estimating classification
errors for feature selection. Incorrect estimates can lead to false identification or igno-
rance of relevant biomarkers [10]. Model selection involves choosing the appropriate
classifier and parameters in order to maximize the classifier’s ability to generalize.
The number of features, or dimension size of samples, also affects the ability of a
classifier to generalize. Usually, there is an optimal number of features for specific
classifier and data combinations [57]. Parameters that affect classifier complexity,
e.g. the radial basis kernel parameter, should be fine-tuned to individual datasets.
As the complexity of a classifier increases, training error tends to decrease. However,
this decrease in training error is also accompanied by an increase in testing error [52].
We can identify classifier parameters corresponding to optimal testing error by using
cross validation methods.
Several studies have examined the effect of small sample size on wrapper methods.
This problem, inherent in high-throughput expression data, can cause high variabil-
ity in estimated classification errors. Subsequently, this leads to high variability in
ranking results among different methods [10, 128]. Braga-Neto et al. compared cross
validation, resubstitution (training error), and bootstrap methods using simulated
small sample expression data [10]. They found that cross validation is highly variable
due to variations in small sample data resulting from hold-out testing. Although the
high variability problem does not exist for resubstitution–resubstitution is low-biased,
i.e. classification error estimates are lower than the true error. Bootstrap estimators
have a lower variance and are unbiased, but are computationally expensive [10, 44].
Braga-Neto et al. proposed a new method, called bolstering, to correct estimation
bias due to small sample size while maintaining computational efficiency [9]. Addi-
tionally, Fu et al. showed that bootstrap cross validation (BCV) performs better than
both bootstrap and cross validation, but is very computationally intense [44]. Each
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of these methods may be appropriate under certain data conditions and should be
selectively considered depending on available computational resources.
2.4 Combining Heterogeneous Microarray Datasets
In order to alleviate the sample size problem, we often want to combine high-throughput
expression data from separate, but similar studies. For example, we can combine
Affymetrix microarray data at a low level using software applications such as RMA
Express [7], dChip [79], or caCORRECT [137] provided that all microarray samples
are of the same platform. Some of these software applications include quality control
in the gene expression computation process. However, data can be difficult to combine
because of technological variability in cases where there is no standard protocol.
Because there is no standard microarray platform, different studies often use dif-
ferent platforms resulting in gene expression measurements that are not directly com-
parable [24]. Even experiments using the same platform may produce different expres-
sion values due to variations in assay protocols or in samples between laboratories.
Several studies have attempted to combine microarray data after computing gene
expression values. For example, Park et al. used ANOVA to identify sources of vari-
ation between microarray experiments from different laboratories that use the same
platform [100]. Once they adjusted their model to account for unwanted variations,
they identified differentially expressed biomarkers in datasets from three different
laboratories. Choi et al. combined gene expression values from multiple microarray
studies by computing the effect size of variations comparable between datasets [24].
The benefits of combining microarray datasets have been illustrated using cancer gene
expression data. Xu et al. identified differentially expressed biomarkers for prostate
cancer using several datasets and Wang et al. did the same for leukemia [152, 147].
Phan et al. extended the method by Wang et al. to wrapper-based methods using a
bootstrap approach to combine ranking estimates weighted by the standard deviation
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of the measurement [104].
When we are limited to only a small amount of data, we may only identify some of
the relevant biomarkers. Furthermore, different datasets may produce different lists of
relevant biomarkers. By combining several smaller datasets, we not only increase the
statistical significance of biomarker selection, but also gain a more global perspective
of the problem.
2.5 Predictive Diagnostic and Prognostic Models
There are several studies that examine the general feasibility of disease classification
using microarrays [111, 88, 97, 131, 33, 77]. Some of these studies focus on the analyt-
ical and machine learning aspects while others focus on the clinical utility. Dudoit et
al. used three microarray datasets to test a variety of classifiers including Fisher linear
discriminant, maximum likelihood discriminant, nearest neighbors (KNN), classifica-
tion trees, and aggregating classifiers [33]. Their results indicate that simple classifiers
such as KNN and linear discriminants generally perform as well or better than more
complicated classifiers. In fact, many microarray and related high-throughput data
classification studies have used the simple KNN classifier [118, 23, 75, 109]. Ntzani
et al. reviewed 84 studies that attempted to correlate clinical cancer outcomes to
gene expression profiling. Results from these 84 studies were variable. However,
because microarray studies were relatively new at the time, data sample sizes were
small and validation of results rare [97]. The reviews by Simon and Quackenbush et
al. examine key steps and common pitfalls involved in building clinically predictive
models [111, 131]. Notably, Simon stresses the importance of correctly estimating
the accuracy of prediction models on future samples. This involves proper division
of samples into training and testing sets prior to any analysis such that resulting
prediction models will not have “seen” any information about testing samples. The
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study by Michiels et al. reinforces this recommendation after they re-analyzed sev-
eral large cancer prediction studies [88]. Their results indicated that many of these
studies predicted no better than random chance. They discovered that the selection
of features greatly depends on the samples and recommended a method of repeated
random sampling to better estimate the mean and variance of prediction error. Gen-
erally, the correct protocol of building a predictive model is well established and the
pitfalls of the process repeatedly outlined [132, 2, 145]. However, even following the
protocols may lead to poorly performing models due to the vast set of parameters
and algorithms available at each step of the process.
2.6 Improving Biological Relevance by Integrating Knowl-
edge
Some investigators have attempted to improve feature selection by using biological
knowledge. Purely data-driven feature selection methods require a sufficient num-
ber of patient samples in order to adequately cover the problem space. Because the
problem space for high-throughput data is exponentially large, feature selection al-
gorithms that rely on both data and knowledge tend to perform better [149]. There
are some examples of this phenomenon in the literature that are specifically targeted
at feature selection [106, 21, 107]. Many other examples exist that are somewhat
related.
Aerts et al. combined data from several resources to prioritize genes relevant to
diseases of interest [1]. Their data sources included Gene Ontology databases, pub-
lished literature, microarray repositories, and sequence information. They extracted
“training” genes–genes tagged as differentially expressed in or related to the biologi-
cal problem–from these databases and ranked test genes according to their similarity
to the training genes. Kuffner et al. identified groups of genes that simultaneously
correlate to genes mentioned in relevant literature and to differential components of
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expression profiles [72]. Kong et al. searched for combinations of genes that are dif-
ferentially regulated based on multivariate Hotelling’s T 2 statistic and that correlate
with Gene Ontology and other pathway databases [71]. Mukherjee et al. developed a
theoretical framework to compare feature ranking metrics in the presence of control
features [93]. Chen et al. modified an independent component analysis (ICA) method
for detecting biomarkers using inferred biological knowledge [21]. They showed that
their knowledge-guided method improved the efficiency of detecting biomarkers com-
pared to traditional ICA methods. Both of these studies are similar to the study by
Phan et al., in which biological knowledge in the form of validated biomarkers were
used to identify the best feature ranking method out of a population of methods.
The authors showed that a knowledge-guided iterative approach to feature selection
improved the efficiency of identifying relevant biomarkers [106].
2.7 Bioinformatics Systems and Software Applications
Biomarker identification generally follows a commonly established sequence of steps–
the biomarker identification pipeline. In order to understand the scope of this pipeline
and the obstacles that prevent its use in clinical practice, we summarize the pipeline
with examples of existing solutions for each step. Primarily, we focus on bioinfor-
matics tools available as web-based applications. These tools are developed with a
focus not only on new algorithms, but also on the integration of multiple analytical
methods into a user-friendly, web-accessible interface. Indeed, many new bioinfor-
matics applications generally do not introduce new algorithms. Instead, they focus
on the usability and accessibility of their application, an attribute that is increasingly
important as the gap between clinical applications and bioinformatics narrows.
The first step in the biomarker identification pipeline is quality control. Due to the
stochastic nature of high-throughput data, it is important to assess data quality prior
to analysis. Moreover, the large quantity of high-throughput data requires specialized
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software applications. There are several existing applications that assess data quality,
particularly for microarrays, within a population of samples while simultaneously
estimating and normalizing gene expression. These applications vary in terms of
modeling complexity and usability, ranging from downloadable software packages–
RMA Express [62], dChip [78]–to web-based applications such as caCORRECT [137].
Although gene expression assays are generally reproducible [126], statistical artifacts
in smaller datasets should be identified and either corrected or removed prior to
further data analysis.
Early in the microarray era, bioinformatics tools often focused on unsupervised
clustering, reflecting researchers’ interest in exploring a new technology and discov-
ering interesting properties in the structure of the data without dwelling on potential
clinical applications. For example, Eisen et al. developed a software application that
combines several types of unsupervised clustering methods [38]. AMIC@, a more
recent development, also focuses exclusively on clustering. However, AMIC@ com-
bines clustering algorithms as well as visualization tools into a web-based application
[48]. Clustering algorithms have not evolved significantly to this day. However, we
have increasingly applied clustering to high-throughput gene expression data from
many different clinical scenarios. These investigations have led to significant findings
in clinical applications, especially in studies concerning cancer subtype identification
[30, 29]. As such, unsupervised clustering applications are still widely used for data
visualization and discovery.
More recently, the focus of microarray analysis has shifted away from unsupervised
clustering to the more guided and powerful supervised analysis. Consequently, web-
based bioinformatics applications have also shifted. These new tools focus on genes
differentially expressed between known conditions. Some are specific to microarray
platforms. For example, MAGMA and ILOOP are web-based applications designed
to analyze two-channel microarrays [114, 108]. ILOOP is an interface that assists
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in experimental design of two-channel microarrays while MAGMA incorporates stan-
dard normalization and statistical methods into an application whose primary aim
is usability and reproducibility. Not surprisingly, many of these web-based applica-
tions implement functionality for several common steps in the data analysis pipeline.
GEPAS (Gene Expression Profile Analysis Suite), for example, includes functions that
address several aspects of microarray analysis, including data normalization, feature
selection, class prediction, and even unsupervised clustering [139]. CARMAweb is yet
another recent development for microarray analysis [113]. CARMAweb uses modules
from Bioconductor, an open-source bioinformatics software package that leverages
the R programming language. The microarray analysis functions in Bioconductor
include background correction, quality control, normalization, differential gene de-
tection, clustering, dimensionality reduction, and visualization [47]. Again, as with
most bioinformatics applications, CARMAweb’s contribution to the bioinformatics
community is an integration of many tools into a user-friendly web interface. Yet
another compilation of many gene expression analysis tools is GenePattern [115].
GenePattern, however, furthers the concept of usability and reproducibility by inte-
grating with the cancer Bioinformatics Grid (caBIG), an initiative by the National
Cancer Institute (NCI) to create a standard for semantic interoperability of bioinfor-
matics software [95]. Despite the existence of many web-based tools for biomarker
identification, we are still several steps removed from clinical applications. Before us-
ing these clinical biomarkers in clinical scenarios, we must interpret and verify their
biological validity.
It is known that lists of candidate biomarkers from feature selection studies de-
pend on both the available samples as well as the selection algorithm [88]. In fact,
these lists may be highly unstable. Furthermore, high-throughput assay platforms
typically consist of tens of thousands of genes, many of which are still not fully un-
derstood. Thus, the task of interpreting these results is daunting. By associating
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each candidate gene to a biological function, we can begin to understand 1) the un-
derlying mechanisms of the associated disease and 2) the biological relevance of the
feature selection algorithm. Databases such as the Gene Ontology (GO) are designed
to facilitate interpretation on a large scale [46]. However, there is no single method to
extract statistically significant conclusions from a GO database analysis. Analogous
to quality control, clustering, and feature selection algorithms, GO tools are diverse.
Some of these tools, all available as web-based or downloadable software, including
GoMiner [154, 155], GOStat [4], AmiGO [18], BiNGO [86], and GOEAST [157]. Each
of these tools varies in statistical methodology for determining over-representation of
functional GO categories as well as in usability and available software features. Fortu-
nately, the community has recognized the difficulty in choosing a particular software
package, resulting in applications such as SerbGO [91]. SerbGO assists researchers by
narrowing the list of existing GO applications depending on their specific data analy-
sis needs. There are also similar applications that mine literature rather than the GO
database. CoPub, for example, links lists of candidate genes to keywords obtained
from literature in Medline abstracts and visualizes statistically over-represented key-
words using a network structure [43].
With the steady accumulation of large amounts of gene expression data, several
applications have emerged that organize and integrate these data sources and hetero-
geneous datasets more effectively. As previously mentioned, increasing data sample
size is a way to increase the reproducibility of the resulting predictive models. Thus,
there has been a demand for data sharing solutions. The Gene Expression Omnibus
(GEO) [35] and ArrayExpress [101] are examples of large repositories that adhere to
community data standards such as MIAME [11]. ArrayWiki is an alternative solution
that allows the user community to annotate gene expression metadata [138]. caArray
is part of the caBIG initiative and is intended to become a semantically interoperable
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standard for microarray storage for caBIG applications [95]. Just as there is an over-
lap of analytical methods in gene expression analysis software and gene interpretation
software, there is an overlap of data in these high-throughput data repositories. Con-
sequently, we are not surprised to acknowledge the existence of an application called
the ‘Microarray Retriever’ [66]. This web-based application retrieves gene expression
data from both the GEO and ArrayExpress repositories in order to maximize the po-
tential for large-sample microarray studies. Similarly, GEOmetadb is an improvement
on the querying capabilities of the GEO repository [158]. Although it is currently
only available for GEO, it is easy to see that meta-analysis applications are becoming
increasingly useful.
The availability of many software packages for each step in the biomarker iden-
tification pipeline enables us to choose from a variety of methods to suit our needs.
However, the lack of an established data standard impedes our progress when we try
to fit the pieces together [98]. For example, without translating the data format, we
may not be able to use the data output of a quality control and normalization appli-
cation in a subsequent clustering or feature selection application. Furthermore, we
sometimes need to translate lists of gene symbols from a feature selection application
before interpretation with a particular GO application. Workflow applications such
as GeneTrailExpress and Taverna address this issue in different ways. GeneTrailEx-
press is a comprehensive web-based application that implements its own normaliza-
tion, statistical analysis, interpretation, and visualization modules based on common
methods [69]. Taverna is more general and builds workflows for caBIG certified web
services [59]. The goals of these workflow applications support those of translational
research by speeding up the process by which bioinformaticians can assess the clinical
feasibility of a particular data-specific workflow. Furthermore, these workflows may
potentially simplify the analytical process for clinicians by establishing predefined
algorithm parameters known to work well for particular clinical situations.
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CHAPTER III
IMPROVING MICROARRAY DATA SAMPLE SIZE BY
COMBINING DATASETS
3.1 Introduction
Microarray gene expression profiling has become a popular tool for identifying biomark-
ers in diseases such as cancer. They allow us to examine the expression levels of thou-
sands of genes in a single experiment. However, cancer may only alter a tiny portion
of the human genome. Therefore, we need a powerful and effective feature selection
scheme, in addition to a large sample size, to identify these potential biomarkers.
While the number of gene expression datasets available to the scientific community
is growing, the sample size of each dataset remains small compared to the number
of features. As such, methods for combining multiple datasets have the potential for
increasing the power of microarray data analysis by pooling information.
Combining datasets can be difficult when we use different microarray platforms
or apply different probe normalization and summarization techniques. Even when we
use the same microarray hardware and software, the laboratory effect can, in some
cases, be more significant than the choice of microarray platform when assessing
reproducibility [64]. Differences in reproducibility, sensitivity, and specificity between
datasets from separate test sites can lead to different sets of candidate biomarkers
[103, 146]. In addition to all of these technical obstacles, the practical limitation
of finding datasets which measure the same scientific question further hampers data
combination. Thus, most current biomarker identification studies are limited to single,
small-sample datasets.
A common goal in microarray analysis is the creation of predictive classifiers. The
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first step in creating a classifier is often feature selection, which involves systemati-
cally excluding a number of weakly-informative genes in order to increase the overall
performance of the classifier. Methods for feature selection fall into two categories:
filter methods and wrapper methods.
Filter methods are a two step process, beginning with individual scoring of each
feature, followed by selection based on this scoring. At the end of the filtering pro-
cedure, we build a predictive classifier using a different method from the one used
to score and select individual genes. Common filtering methods include fold change
and t-test. However, the classification accuracy of biomarkers resulting from such
methods is not necessarily high. Because of the inclusion of redundant information,
resulting classifiers may become highly complex without significant gain in accuracy
[151]. Furthermore, these methods are sensitive to small-sample data and depend on
strict assumptions. Calculation of the t-statistic, for example, breaks down when the
number of features included is larger than the sample size. Statistics such as mean
and variance may be significantly biased when calculated from small sample data,
leading to false conclusions of significance. The dependence of the t-test on data nor-
mality is also problematic, since this assumption is often not true for gene expression
data [140].
For wrapper methods, the final classifier is intrinsic to the feature selection process.
Instead of scoring genes independently, a wrapper method will assess groups of genes
based on their synergistic performance, usually measured by estimating the error-rate
of classification. Using classification error-rate as a selection criterion is appropriate
when the aim is to design a discriminant rule [150]. Furthermore, error estimation
techniques such as the bootstrap do not depend on assumptions of data normality.
Studies have shown that various bootstrap and cross validation resampling methods
are accurate estimators of predictive performance for small-sample data [10].
Several studies examine methods for combining multiple microarray datasets in
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order to improve sample size. These methods include large-scale data-mining, func-
tional integration, ANOVA models, and effect size meta-analysis [100, 147, 60, 153].
Of particular interest is the study by Wang et al., which combined the fold change of
genes between classes from three microarray datasets. Their computed statistic also
accounted for the different variances within datasets [147]. Choi et al. computed a
combined z-statistic and found that their combined statistic identifies more potential
biomarkers than those of single datasets [24]. None of these methods, however, ex-
plored data combination using wrapper-based gene selection methods that estimate
classification error. Such methods would have both the benefits of accurate identi-
fication of predictive genes from small datasets as well as increased sample size by
combining multiple datasets.
The meta-analytic method that we propose combines heterogeneous microarray
datasets by combining bootstrap estimated classification errors for each gene. Our
method, adapted from Wang et al., weights the combined classification error from
each dataset by the inverse of its bootstrap variance [147]. This weighting reduces
the overall contribution of datasets with large variance. It is easily extended to any
number of datasets and has the potential to improve the biological and statistical
relevance of candidate biomarkers.
3.2 Methods
3.2.1 Microarray Data
We use two groups of microarray datasets to test the bootstrap meta-analysis method.
The first group includes samples from two renal cancer studies. Each study contains
samples from clear cell (CC), chromophobe (CHR), and oncocytoma (ONC) renal
cancer subtypes. We are interested in identifying genes that are differentially ex-
pressed between the CC and the combined group of both CHR and ONC subtypes.
The smaller dataset from Schuetz et al. contains 13 CC, 4 CHR, and 3 ONC samples.
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The larger dataset from Jones et al. contains 32 CC, 6 CHR, and 12 ONC samples.
Samples from both datasets are derived from Affymetrix microarrays and contain at
least 8793 genes [124, 67]. The Jones dataset contains more genes, but we reduce the
number of genes to a subset of 8793 common to both datasets.
The second group includes two prostate cancer datasets with 12625 genes on
Affymetrix microarrays. Between the two datasets, there are a total of 113 tumor
samples and 113 normal samples [133, 19]. Normal samples are extracted from tissue
adjacent to prostate tumors. The smaller Singh dataset contains 52 tumor samples
and 50 normal adjacent samples. The Chandran dataset contains 61 tumor samples
and 63 normal adjacent samples.
3.2.2 Feature Ranking
We use a wrapper-based approach to rank genes by classification accuracy, estimated
using a linear support vector machine (SVM) classifier and bootstrap resampling [28].
The SVM classifier predicts the class of a test sample based on its gene expression
by constructing a maximal margin discriminating hyperplane from training samples.
We use a dataset-specific SVM cost parameter, C, of approximately 1/n. Thus, the
cost parameter is 0.05 for the Schuetz dataset and 0.02, 0.01, and 0.01 for the Jones,
Singh, and Chandran datasets, respectively.
The true classification error for a gene, k, given a classifier is E·,k. However, the
true error is unknown since we are limited to a finite sample space within a dataset, j.
We can compute an estimate of the true classification error Ej,k for a dataset, j, and
gene, k, using a bootstrapping method. For a dataset with n = 1 . . .N samples, the
bootstrap algorithm randomly selects N samples with replacement [36]. The unique
N∗ samples selected by bootstrapping (N∗ < N) are designated as the training set,
Straining, while the remaining N − N
∗ samples are the testing set, Stesting.
We define the mth estimate, Ej,k,m, of the true error of classification computed
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with training and testing sets randomly partitioned into Smtraining and S
m
testing. m
enumerates all possible partitions of the data into training and testing sets. To
estimate Ej,k, we repeatedly permute the training and testing sets and compute the







Here, Lmj,n is the predicted class label of sample n from the testing set S
m
testing after
training with the set Smtraining. Lj,n is the true class label of the sample n in dataset j.
We consider only binary classification, in which the labels may take the values of 0 or

















In wrapper-based feature selection, we can use the mean error estimates for feature
ranking and variance estimates as measures of confidence in these classification errors.
3.2.3 Data Combination
Differences in sample size prevent us from directly comparing wrapper-based feature
selection between two or more datasets. The distribution of over all genes k often
depends on the balance of samples between classes within a dataset as well as the
classifier parameters. Furthermore, the total number of samples in a dataset affects
σ2j,k. Thus, we need to empirically estimate a null distribution of classification errors
for genes in each dataset in order to generate a universally comparable (and com-
binable) significance score. A common method for estimating the null distribution,
E0j,k, is to randomly permute the dataset class labels for each gene and re-compute
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the bootstrap, removing any information that the true class labels hold. Normally,
we should compute multiple permutations for each gene to estimate a gene-specific
null distribution. However, because we are interested in the null distribution across
all genes, one permutation per gene is sufficient and computationally efficient. The









where Lm∗j,n and L
∗
j,n are randomly permuted class labels. The corresponding mean
and variance over B = 100 bootstrap iterations are E0j,k and s
0
j,k. Over all k genes,
the sample mean and variance of the null distribution are Ē0j and ŝ
0
j . We can now
normalize any bootstrap estimated error Ej,k against its null distribution such that







The variance of a bootstrap measurement σ2j,k estimates the reliability of that mea-
surement. Generally, as sample size increases, bootstrap variance decreases. Thus,
when combining bootstrap measurements from multiple data sources for a single gene,
we should favor measurements with low variance. Therefore, the combined classifica-
tion score is a weighted combination of normalized bootstrap errors from individual






























We can identify differentially expressed genes from individual datasets by ranking
values of Zj,k for all genes k or by estimating p-values using the estimated null dis-
tribution Z0j,k. Similarly, we can identify significant genes from combined datasets by
ranking values of Ecomb,k for all genes k, or by estimating p-values using the estimated






I(Z0j,i < Zj,k) (9)
where ` is the total number of genes in the dataset. Likewise, the empirical p-value






I(E0comb,i < Ecomb,k). (10)
In addition to the bootstrap error method described above, we combine data
sources on the basis of fold change and t-test as described by Wang et al. [147].
Figure 4 summarizes the data combination scheme.
3.2.4 Validating the Relevance of Gene Ranking
We assess the effect of data combination by comparing the result of feature selection
in each individual dataset to that of the combined dataset. It is often difficult to
compare feature selection between methods or similar datasets due to the large num-
ber of features and the subjectivity of feature interpretation. Because of our limited
understanding of biological mechanisms and the noise inherent in microarray tech-
nology, we can often only verify the validity of a selected gene by independent assays
such as qRT-PCR [25]. However, in order to avoid the costly and time-consuming
validation of genes selected in this study, we use a method introduced by Mukher-
jee et al. to compute the probability of successfully selecting differentially expressed
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Figure 4: Data Combination Method. Estimated gene scores are combined
using a weighted average. Weights are proportional to the standard deviation of the
estimate.
genes [93]. This method is based on a simple scenario that compares the ranks of two
genes, one of which is known to be differentially expressed. Mukherjee et al. com-
putes the probability that a given ranking algorithm correctly ranks the differentially
expressed gene by ranking it more favorably. They extend this method to multiple
genes and define the random variables T0 and T1, which represent the ranks of null
and differentially expressed genes, respectively. Assuming that a higher rank number
corresponds to a more differentially expressed gene, they explicitly compute the prob-
ability, P (T0 < T1), which they call the Binary Selection Accuracy (BSA) [93]. This
probability is equivalent to the area under the curve (AUC) of a receiver-operator
characteristic (ROC) curve produced by classifying genes into either differentially
expressed or null groups using a rank threshold [8].
Instead of comparing different ranking algorithms, we compare the ranks produced
from individual datasets to those of the combined dataset. In order to compute the
BSA, we need a set of reference genes that are known to be differentially expressed.
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For both the renal cancer and prostate cancer datasets, we identify genes from lit-
erature that have also been validated with qRT-PCR, the most common method for
validating differentially expressed genes [90]. When computing the ROC curves, we
weight each gene by one minus its p-value. Thus, statistically significant genes have
a larger contribution to the resulting AUC.
3.3 Results and Discussion
3.3.1 Bootstrap Meta Analysis
Data suggests that the no-information null distribution of the bootstrap is approx-
imately normal, but the actual distribution of errors trained on correct class labels
is skewed toward low error (Figure 5). This is expected, as the magnitude of skew
should be a function of the separability of the classes under investigation and the
information content of the genes present on the microarray.
For the prostate cancer datasets, this skew is less prevalent, as the empirical
distribution more resembles the null distribution. Small deviations still exist at the
low error side of the distribution, corresponding to potential differentially expressed
genes (Figure 6).
3.3.2 Validating the Relevance of Gene Ranking
We identify several validated genes for both the renal and prostate cancer datasets and
use these genes as a reference for assessing the effect of data combination. We restrict
these reference genes to those validated with qRT-PCR. This restriction improves the
reliability of the reference genes since qRT-PCR is a common and established method
for validating microarray assays [90].
In renal cancer, carbonic anhydrase IX (CA9) and low density lipoprotein-related
protein 2 (LRP2) are up-regulated in CC compared to the ONC and CHR renal
cancer subtypes [124, 22]. Additionally chloride channel Kb (CLCNKB), defensin
beta 1, and parvalbumin (PVALB) are up-regulated in ONC and CHR compared to
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Distribution of Bootstrap Error Estimation






(a) Distribution of Schuetz renal cancer bootstrap errors.






Distribution of Bootstrap Error Estimation






(b) Distribution of Jones renal cancer bootstrap errors.
Figure 5: Distributions of normalized classification errors for the renal cancer
datasets. Solid lines represent individual or combined distributions while dashed
lines represent null distributions. Both the Schuetz (5(a)) and Jones (5(b)) datasets
deviate significantly from the null distributions, indicating a large number of dif-
ferentially expressed genes. This deviation is reflected in the combined data (5(c),
continued on the next page).
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Distribution of Combined Bootstrap Error Estimation
Renal Cancer Data





(c) Distribution of combined renal cancer bootstrap errors.
Figure 5 part (c). Parts (a) and (b) and full caption on the previous page.
Table 1: Validated renal cancer reference genes.
Gene Regulation Source
CA9 Up in CC Chen 2005
CLCNKB Up in ONC/CHR Chen 2005
DEFB1 Up in ONC/CHR Schuetz 2005
LRP2 Up in CC Schuetz 2005
PVALB Up in ONC/CHR Chen 2005
Table 2: Validated prostate cancer reference genes.
Gene Regulation Source
AMACR Up in Tumor Ernst 2002
PLA2G7 Up in Tumor Ernst 2002
HPN Up in Tumor Ernst 2002
PYCR1 Up in Tumor Ernst 2002
SCGB1A1 Down in Tumor Ernst 2002
TRIM29 (ATDC) Down in Tumor Ernst 2002
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Distribution of Bootstrap Error Estimation






(a) Distribution of Singh prostate cancer bootstrap errors.








Distribution of Bootstrap Error Estimation






(b) Distribution of Chandran prostate cancer bootstrap errors.
Figure 6: Distributions of normalized classification errors for the prostate cancer
datasets (Singh (6(a)), Chandran (6(b)), combined (6(c), continued on the next
page)). Compared to the renal cancer datasets, these datasets do not deviate signifi-
cantly from the null distribution.
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Distribution of Combined Bootstrap Error Estimation
Prostate Cancer Data





(c) Distribution of combined prostate cancer bootstrap errors.
Figure 6 part (c). Figure parts (a) and (b) and full caption on the previous
page.
CC (Table 1) [124, 22]. Using these reference genes, we compute the BSA (AUC) for
each of the individual and combined renal datasets. We compare the results of the
bootstrap meta-analysis to the original fold change combination method by Wang et
al. as well as to a similar t-test method [147]. The ROC curves (Figure 7) for the
combined data are more similar to the Jones dataset when using T-test or bootstrap
ranking. ROC curves for the fold change method are similar between both individual
datasets and the combined dataset. BSA values (Figure 9) for the combined dataset
are higher than both of the individual datasets when ranking genes using fold change
and bootstrap methods, but not the t-test method. Fold change tends to perform
well for both individual datasets in terms of favorably ranking the reference genes.
Thus, we also expect fold change to perform well for the combined data.
Compared to the Jones data, the small sample size of the Schuetz data seems
to reduce the efficiency of ranking using the t-test and bootstrap methods. Small
sample size generally corresponds to higher measurement variance. Therefore we
expect the data combination method to reduce the overall contribution of the Schuetz
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Weighted ROC Curves for Detecting Validated Biomarkers












(a) ROC curves for detecting reference renal cancer genes after t-test
data combination.







Weighted ROC Curves for Detecting Validated Biomarkers












(b) ROC curves for detecting reference renal cancer genes after fold-
change data combination.
Figure 7: ROC curves for detecting validated reference genes for renal cancer. Red
lines are combined data and dashed lines are individual datasets. For all datasets,
fold change (7(b)) tends to detect reference genes more efficiently compared to t-test
(7(a)) and bootstrap (7(c), continued on the next page). Combining data using fold
change and bootstrap slightly improves detection efficiency. This corresponds to an
increase in area under the ROC curve.
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Weighted ROC Curves for Detecting Validated Biomarkers












(c) ROC curves for detecting reference renal cancer genes after bootstrap
data combination.
Figure 7 part (c). Figure parts (a) and (b) and full caption on the previous page.
data. However, the BSA for the t-test combination method is higher than that of
the individual Schuetz dataset and lower than that of the individual Jones data.
This suggests that, for the t-test method, the contribution of the Schuetz data to
the combined data ranking has not been properly weighted to account for its higher
variance. The results of bootstrap ranking using individual datasets produces similar
BSA values compared to the t-test. However, our bootstrap method properly weights
the Schuetz data to reduce its overall contribution in the combined data. Thus, the
BSA of the combined data ranking is higher than both individual datasets (Figure
9).
For the prostate cancer data, we select six validated genes from literature, four of
which are over-expressed in tumor tissue while two are under-expressed (Table 2) [39].
We compute the ROC curves and BSA scores for the prostate cancer datasets using
these reference genes (Figure 8, Figure 10). Compared to the renal cancer data,
detection of these reference genes via ranking is much less efficient, resulting relatively
38







Weighted ROC Curves for Detecting Validated Biomarkers












(a) ROC curves for detecting reference prostate cancer genes after t-test
data combination.







Weighted ROC Curves for Detecting Validated Biomarkers












(b) ROC curves for detecting reference prostate cancer genes after fold-
change data combination.
Figure 8: ROC curves for detecting validated reference genes for prostate cancer.
Red lines are combined data and dashed lines are individual datasets. Combined data
does not improve efficiency of reference gene detection when using the t-test (8(a))
or fold change (8(b)) methods. The bootstrap method (8(c), continued on the next
page) slightly increases detection performance of the reference genes for combined
data.
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Weighted ROC Curves for Detecting Validated Biomarkers












(c) ROC curves for detecting reference prostate cancer genes after boot-
strap data combination.
Figure 8 part (c). Figure parts (a) and (b) and full caption on the previous page.













BSA, Probability of Correct Gene Ranking, Renal Cancer Data
Figure 9: BSA (AUCs) of individual and combined renal cancer datasets for detect-
ing reference genes. The red bars are AUCs of the combined data. T, FC, and BS
correspond to t-test, fold change, and bootstrap, respectively. S, J, and C correspond
to Schuetz, Jones, and combined data, respectively. For the fold change and boot-
strap (middle and right bar triplets), the relevance of ranking for the combined data
is at least as good, if not better, than both individual datasets.
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BSA, Probability of Correct Gene Ranking, Prostate Cancer Data
Figure 10: BSA (AUCs) of individual and combined prostate cancer datasets for
detecting reference genes. The red bars are AUCs of the combined data. T, FC,
and BS correspond to t-test, fold change, and bootstrap, respectively. S, Ch, and
C correspond to Singh, Chandran, and combined data, respectively. The bootstrap
combination method (right triplet of bars) outperforms both the t-test and fold change
methods.
low BSA scores. This decrease in efficiency may be due to biological heterogeneity
among the three datasets from Singh, Chandran, and Ernst [133, 19, 39].
Despite the low BSA scores, the genes identified from the Ernst dataset have been
qRT-PCR validated and should serve as a point of reference for assessing the quality
of the Singh and Chandran datasets. Examining the ROC curves and the correspond-
ing BSA values, for both the t-test and fold change data combination methods, we see
that combining data improves gene detection compared to the individual Chandran
dataset. However, for these ranking methods, the combined dataset still performs
worse than the individual Singh dataset. The bootstrap method performs equally
well on both the individual Singh and Chandran datasets. Furthermore, the com-
bined method improves the overall performance of gene detection compared to both
individual datasets.
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3.3.3 Interpretation of Selected Genes
Data combination using bootstrap meta-analysis improves the ranks of two of the
prostate cancer reference genes. Both of these genes, tripartite motif containing 29
(TRIM29) and pyrroline-5-carboxylate reductase 1 (PYCR1), were previously vali-
dated by Ernst et al. [39]. For TRIM29, individual dataset p-values of 0.07 and 0.05
are reduced to 0.02 in the combined data. Likewise, for PYCR1, individual dataset
p-values of 0.19 and 0.16 are reduced to 0.10 in the combined data. The ranks for
the other four reference genes are not improved in the combined data compared to
both individual datasets. However, the individual dataset p-values of these four genes
are larger than those of TRIM29 and PYCR1. Although these genes have been val-
idated with qRT-PCR, their reliability for these particular datasets is questionable
and provides further evidence of the analytical difficulties due to prostate tissue het-
erogeneity.
In addition to the reference genes, we identify several other prostate cancer-related
genes using the bootstrap-combined data. Interestingly, brain-derived neurotrophic
factor (BDNF), has been linked to prostate cancer [13]. We easily identify BDNF in
the Singh dataset (rank=3), but not in the Chandran data (rank=420). The com-
bined data ranks the gene at 17 (lower rank is better). Similarly, the combined data
improves the recognition of the metastasis-associated protein 1 (MTA1, combined
rank=18, Singh rank=16, Chandran rank=360) and chemokine receptor 2 (CCR2,
combined rank=35, Singh rank=5, Chandran rank=580), again by discounting the
contribution of the Chandran data [55, 83]. The combined data also favorably ranks
some relevant genes that are not ranked favorably in individual datasets. For ex-
ample, ITIH3 (Singh rank=25, Chandran rank=326, combined rank=6) and CHD5
(Singh rank=165, Chandran rank=95, combined rank=7) have both been linked to
human cancer [51, 3].
Data combination also improves the ranks of two of the renal cancer reference
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genes, CLCNKB and PVALB. The rank of DEFB1 is only improved compared to the
individual Schuetz dataset (Schuetz rank=6158, Jones rank=552, combined data=1011).
However, the p-value of DEFB1 in the Schuetz dataset is large. Likewise, the com-
bined data rank of CA9 is improved compared to the Jones dataset, but not the
Schuetz dataset (Schuetz rank=1900, Jones rank=2808, combined data=2344). Some
genes implicated in renal cancer are favorably ranked in the combined data, but not in
either of the individual datasets. For example, CXCR4 has a combined data rank of
28, but individual ranks of 113 and 188 in the Schuetz and Jones dataset, respectively
[123]. Many other examples of improved biological relevance exist in both prostate
and renal cancer datasets. However, a more rigorous biological analysis is beyond the
scope of this paper.
3.4 Conclusion
Until microarray technology becomes standardized, we must develop statistical meth-
ods to handle small sample data. Standardization protocols are currently not well
defined. However, the ideal scenario for standardization should allow us to com-
pare quantitative measurements across different platforms or to expect all clinical
measurements to be acquired with the same technology. Regardless of standardiza-
tion, microarrays are still subject to technological variance when experiments are
performed at different times or locations. Our proposed method is a possible solution
to reduce technical bias by computing differential gene expression scores on distinct
microarray groups, then combining these scores across multiple groups of microar-
rays. The bootstrap accurately estimates classification errors for genes of individual
small datasets while the combination method favors genes whose scores have lower
individual dataset variances. The results of this method applied to prostate and
renal cancer datasets indicate that bootstrap meta-analysis improves the biological
relevance of gene selection by increasing data sample size.
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CHAPTER IV
IMPROVING THE EFFICIENCY OF BIOMARKER
IDENTIFICATION USING BIOLOGICAL KNOWLEDGE
4.1 Introduction
The subjective nature of traditional medical techniques limits the accuracy of can-
cer subtype classification and, subsequently, the effectiveness of therapy. Clinicians
visually examine cancer specimens to determine their subtypes before proposing treat-
ment regimens. However, cancers with similar characteristics may behave very dif-
ferently despite similar treatment conditions [50]. Because cancer is the result of
genetic anomalies, emerging diagnostic research has primarily focused on genetic and
proteomic expression. This research generally involves the use of high throughput
technology (e.g. microarrays and mass spectrometry) to generate large amounts of
genetic and proteomic expression data. We typically reduce this data using one of
many analysis algorithms with the goal of identifying a subset of features (corre-
sponding to genes or proteins) with high predictive accuracy [143, 124, 133]. These
feature subsets, if correctly identified, will both enhance our understanding of the bi-
ological mechanisms as well as provide us with an accurate diagnostic system. When
validated, we call these differentially expressed features biomarkers. Unfortunately,
even the selection of a ranking metric is subjective, as different metrics may identify
different subsets of features [10]. Feature ranking affects both the efficiency of iden-
tifying relevant genes and the accuracy of subsequent predictive models. We address
this issue by presenting a method that uses existing biological knowledge to identify
the best feature ranking metric for a particular gene expression dataset. The op-
timal metric maximizes the probability of correctly ranking differentially expressed
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and previously validated genes (Figure 11). Figure 11 illustrates a hypothetical
situation in which prior knowledge enables us to choose between two feature ranking
algorithms. Although this example ranks genes individually, we can generalize it to
combinatorial feature selection. In Figure 11, we assume that genes 8, 52, and 234
have been previously identified and validated for a particular clinical problem. For ex-
ample, if the clinical problem is prostate cancer recurrence, we want to identify genes
from various knowledge sources that are differentially expressed between event-free
survival (survival without symptoms) after a number of years and cancer recurrence.
Among the multiple feature ranking metrics, the “optimal” or biologically relevant
metric should favorably rank these previously validated genes while simultaneously
reducing the number of false discoveries. The chosen ranking metric is only optimal
within the space of tested ranking metrics and available knowledge.
Despite numerous feature selection studies in the literature, there is still a lack
of clinically validated and proven biomarkers for many cancers. Thus, the use of
“correct” genes as knowledge for algorithm selection is subjective and we should
choose these genes carefully. Sources of biological knowledge are abundant, but vary
in terms of reliability. We consider a knowledge source to be reliable if genes (or the
corresponding expressed proteins) from that source have been clinically validated as
differentially expressed. The majority of knowledge is contained in the literature and
we can roughly divide them into four levels of reliability, adapted from a review of
post-analysis validation methods by Chuaqui et al. [25]:
1. No biological validation. As the lowest level of reliability, this includes
studies that develop feature selection algorithms and present the selected list of
genes without a stringent interpretation of the biological results.
2. In silico validation. Also known as computational validation, these studies
compare their feature selection results to the results of other studies. They may
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also identify Gene Ontology (GO) categories that are statistically overrepre-
sented as a result of feature selection.
3. Same-sample validation. These studies validate their microarray experi-
ments by performing additional assays on the same samples from which their
microarrays were derived. These assays typically include quantitative real-time
PCR (qRT-PCR) or northern analysis and serve to validate the technical relia-
bility of the microarrays.
4. Independent or clinical validation. As the highest level of reliability, these
studies validate the results of their microarray experiments using independent
biological samples, usually from a clinical source. Independent validation en-
sures that the selected features are not a result of over-fitting. These validations
often take the form of qRT-PCR and in situ hybridization (ISH) for RNA prod-
ucts, or immunohistochemistry (IHC) and western analysis for protein products.
Despite frequent disagreement between qRT-PCR and microarray results, qRT-
PCR is the most common method for validation of differentially expressed genes.
Genes with large fold-change in microarray data are consistently correlated with qRT-
PCR while those with smaller fold change are more susceptible to technical variability
[90]. The detection of differentially expressed genes is generally reproducible across
several microarray platforms [126]. However, in light of a recent study illustrating
the pervasiveness of technical artifacts in microarray data [137], we only consider a
knowledge source reliable if it falls into category three or four.
Investigators have attempted to improve feature selection by using biological
knowledge. Their knowledge sources often fall into category two of reliability, in silico
validation, and include Gene Ontology and pathway databases, published literature,
microarray repositories, and sequence information. Generally, these studies identify
genes that cluster or correlate with genes from the knowledge sources [1, 72, 71].
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Another study developed a theoretical framework to compare feature ranking metrics
in the presence of control features [93]. However, this study also neglected to focus
on the reliability of the control features. Indeed, the wealth of available information
in the form of gene and protein interactions, functional annotation, and genetic and
pathways can improve the results of data analysis. Furthermore, microarray data
analysis has shifted from purely data driven methods to methods that use additional
knowledge, even in the feature selection process [5].
We develop a method to quantify the efficiency of detecting biomarkers by fea-
ture ranking. This method maximizes the biological relevance of feature ranking by
choosing the best metric from a population of metrics. The chosen ranking metric is
optimal with respect to knowledge obtained from reliable sources. We test the effec-
tiveness of our method using clinical gene expression data. Results indicate that the
choice of ranking metric significantly affects feature ranking, which, in turn, affects
the efficiency of discovering and validating novel biomarkers.
4.2 Methods
4.2.1 Gene Ranking and Selection
Throughout this section, the term ‘gene set’ denotes a group of one or more genes
that act in concert. A ‘sample’ refers to measurements of a gene set from a single
microarray or molecular profile. The entire microarray sample contains ` genes while
a gene set may contain p genes (where p  `). We represent a gene set i for sample n
as vectors, ~xin ∈ R
p, and labels, yn ∈ {0, 1}. The class label, yn, indicates the clinical
source of the microarray sample. In most cancer problems, yn = 1 indicates, for
example, samples measured from patients with cancer and yn = 0 indicates samples
from patients with no cancer. For a microarray dataset with N samples, gene set i
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Ranking Metric 1 Ranking Metric 2
# False Discoveries 2 >6
“Optimal”
Figure 11: Selection of a biologically relevant ranking metric using existing biological
knowledge. The “optimal” method–ranking metric 1–minimizes the number of false
discoveries. False discoveries are genes that have not been validated or that have been
shown to be non-informative.
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gene set using the function
αi = hθ(~di) (11)
where θ ∈ Θ is a meta-parameter that characterizes the scoring function, or ranking
metric. A smaller α indicates a more differentially expressed gene set. We also
constrain α to be in the interval [0, 1], such that the function hθ may be a hypothesis
test that computes a p-value or an estimate of classification error. Although Θ can
represent the space of all ranking methods, we use a reduced set of wrapper-based and
filter methods in our simulations. Specifically, we use three classifiers–support vector
machines (SVM) [28], signed distance function (SDF) [6], and linear discriminant
(LDA)–with various parameters and the common t-test, fold change, and significance
analysis of microarrays (SAM) [141]. Refer to the Appendix for more details about
each classifier. We use the 0.632+ bootstrap to estimate classification error for the
wrapper methods [10, 37]. We discretely vary the classifier parameters over several
values (Table 3).
In practice, a gene expression dataset will have N samples, each with ` features.
We separately examine m feature sets (m can be different from ` and include, for
example, all pairs, triplets, or a subset of feature combinations), corresponding to
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(~d1, ~d2, . . . , ~dm). From the mapping defined in Equation 11, we compute the set of
rank scores for each feature set (α1, α2, . . . , αm). Using a simple selection method, we
can then conclude that the best feature sets and potential biomarkers are in the set
G = {i : α < τ} (12)
where τ is a threshold.
4.2.2 Selection of a Ranking Metric Using Maximum Likelihood
We want to choose a feature set ranking metric, θ, that produces the most biologically
relevant ranking of the m feature sets, (~d1, ~d2, . . . , ~dm), with respect to a given set of
knowledge. Although we may never know the biological relevance of all features in a
dataset, we may infer from literature that the k feature sets, Gk = {g1, g2, . . . , gk},
are relevant, where k  m and the elements of the set correspond to the feature sets
(~dg1,
~dg2, . . . ,
~dgk). Assuming that lower scores are better, the best θ assigns scores
such that hθ(~di) < hθ(~dj) for i ∈ Gk and j 6= Gk, i.e., feature set i is known to be more
biologically relevant than feature set j for this particular dataset. This implies that
the elements of the set {hθ(~di) : i ∈ Gk} should generally be smaller than those of
{hθ(~dj) : j /∈ Gk}. If the knowledge is reliable, we want to choose a θ that maximizes
the probability that the score of a feature set from Gk is less than that of a feature
set that is not from Gk. Explicitly, we define this probability as





for i ∈ Gk and j /∈ Gk. This probability represent the biological relevance score of θ,













where I(x) is the indicator function that evaluates to one when x is true and zero
when x is false. Equation 14 is equivalent to computing the area under an ROC
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curve (AUC) for classifying feature sets as either biologically relevant or irrelevant
[93]. Using this biological relevance function, we can identify the optimal ranking




For a more detailed derivation of maximum likelihood ranking metric selection, refer
to Appendix A.1.
4.2.3 Selection of a Ranking Metric Using Maximum A Posteriori
The maximum likelihood approach to identifying an optimal θ̂ takes all current in-
formation about known feature sets into account when computing the likelihood.
Thus, when we introduce new knowledge, we can combine this new knowledge with
the existing knowledge to recompute the likelihood. However, when introducing new
knowledge, we may also use the probability from a previous knowledge set as a prior
within a Bayesian framework.
For example, suppose that we know, from previous experiments, that some feature
selection methods tend to perform better than others for particular datasets. We can
quantitatively represent this as prior knowledge, P (θ). If the previous experiments









Given only the prior, we can estimate the optimal algorithm in the same manner
as the maximum likelihood method. However, suppose that we are given additional
information about n biologically relevant feature sets, G′n. Then we can update our
beliefs about the feature ranking metrics using the formula for computing a posterior




φ(G′n, θ)P (θ). (17)
For a more detailed derivation of the maximum a posteriori method, refer to Ap-
pendix A.2.
4.2.4 Iteratively Updating Knowledge
The purpose of identifying θ̂ is to use this “optimal” feature ranking metric to identify
and validate new biomarkers. augment our knowledge by identifying new gene sets
that may also be relevant. The optimal θ̂ helps us identify gene sets that are most
likely to be biologically relevant, increasing the overall efficiency of data mining.
It may be difficult to compile a comprehensive list of knowledge from literature
and independent validation. Consequently, we can expect that some feature sets that
are not in our knowledge set, {i /∈ Gk}, are, in fact, relevant biomarkers. We define V
as the set of all relevant biomarkers, regardless of whether their relevance is known.
A feature set is known to be in the set V only after performing a validation procedure
such as qRT-PCR. Figure 12 and Figure 13 are descriptions of the knowledge
update algorithms for both the ML and MAP methods. Refer to Appendix A.1
and A.2 for further details.
initialize knowledge set Gk




identify and validate n new feature sets: G′n
update knowledge set: Gk+n = {Gk, G
′
n}
k = k + n
end while
Figure 12: Iteratively updating knowledge using maximum likelihood.
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initialize knowledge set Gk










while Gk 6= V do




update knowledge set: Gk+n = {Gk, G
′
n}
update prior: P (θ) = P (θ|G′n)
k = k + n
end while
Figure 13: Iteratively updating knowledge using maximum a posteriori.
4.2.5 Assessing the Efficiency of a Ranking Metric
If we know all feature sets in the set V , we can quantify any improvement in efficiency
due to optimization of the ranking metric. Using bootstrap resampling, we randomly
and repeatedly partition the feature sets in V into a group of known relevant feature
sets (training) and a group of unknown relevant feature sets (testing). If there are
K elements in V , we randomly select K elements with replacement, resulting in K∗
(K∗ < K) unique elements for the testing set. We use the group of K − K∗ known
relevant feature sets to optimize the ranking metric, then iteratively detect feature
sets from the unknown set of K∗ features and update our knowledge set. Every
validation test requires a finite amount of time and resources. Plotting the fraction
of correctly validated biomarkers (y-axis) vs. total validation time (x-axis), reveals
that higher detection efficiency corresponds to a larger area under this curve. This
curve is similar to a ROC curve, so we also call the area under this curve the AUC.
We repeat this bootstrap sampling of feature sets 100 times in order to compute
the significance of the differences among three conditions: optimal metric selection,
sub-optimal metric selection, and sub-optimal initial knowledge. For the sub-optimal
metric selection condition, we use correct initial knowledge selected from the set V
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or using the Bayesian maximum a posteriori approach:
θ̂ = argmedian
θ
φ(Gk, θ)P (θ) (19)
Selection of a ranking metric with median AUC represents the practice of arbi-
trarily selecting a metric with no regard for biological relevance and efficiency. This
median AUC algorithm also serves as a reference point for assessing the potential
improvement of efficiency when using the optimal algorithm. For simulations using
clinical data, we directly compare the optimal selection method using maximum like-
lihood or maximum a posteriori to a commonly used filter method such as fold change
or significance analysis of microarrays (SAM) [141].
For the sub-optimal initial knowledge condition, we begin the simulation with
incorrect knowledge selected via bootstrap and use the maximum likelihood or max-
imum a posteriori method to optimize the ranking algorithm before updating the
current knowledge set. We expect the average AUC of the optimal selection con-
dition to be higher than that of both of the sub-optimal conditions. Figure 14
illustrates this process.
To determine whether the optimization procedure is over-fitting to the knowledge
set, we conduct additional tests using randomly selected knowledge sets. If over-fitting
is occurring, results of the optimal, suboptimal, and suboptimal knowledge tests for
randomly selected knowledge should be similar to those of the true knowledge set.
4.2.6 Synthetic Data Simulations
Synthetic gene expression datasets are often used to assess the efficacy of feature
selection algorithms [89, 94, 82]. Clinical gene expression datasets usually suffer from




















Figure 14: Quantifying the efficiency of detecting relevant biomarkers. For clinical
data, we define an initial set of knowledge with K known differentially expressed fea-
ture sets. Using bootstrap cross validation, we partition the knowledge set into K∗
and K − K∗ samples. K∗ is the number of unique samples after sampling from the
knowledge set K times with replacement. We optimize the ranking algorithm using
K−K∗ feature sets and assess the algorithm’s efficiency in detecting the remaining K∗
feature sets. For each of the three conditions–optimal metric selection, sub-optimal
metric selection, and sub-optimal initial knowledge–we perform this bootstrap sam-
pling 100 times in order to compute the significance of any differences between mean
AUC values.
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noise and differential expression until after fully validating the results with external
data. Synthetic datasets allow us to control these properties, replicate experiments,
and compute a confidence interval for the analysis results. One of the caveats of
synthetic data generation is that they must closely resemble true datasets in terms
of gene expression distributions, sample size, and number of features.
In the following synthetic data simulations we use controlled experiments to ver-
ify that using optimally selected ranking metrics improves the efficiency of feature
selection. It is difficult to gauge improvement of feature selection efficiency in clinical
datasets because the distribution of data is unknown. Synthetic datasets for these
simulations have variable sample sizes and consist of 3000 one- or two-dimensional
feature sets. We use a small dataset size of 20 samples divided into two classes (10
samples per class) and a larger dataset size of 40 samples (20 samples per class).
One hundred of these feature sets are distributed such that samples are differentially
expressed between the two classes. The remaining 2900 feature sets are distributed
with no differential expression (Table 4, one-dimensional feature sets and Table 5,
two-dimensional feature sets). In all synthetic datasets, the knowledge set, V , con-
tains 100 differentially expressed feature sets. We model synthetic datasets to be
roughly similar to real expression data in terms of both number of feature sets and
sample size. The number of differentially expressed feature sets is small compared to
the total number of feature sets.
We use six synthetic datasets to examine feature set detection efficiency (Table 6).
The first and second datasets use either linearly or non-linearly separable biomark-
ers for feature sets 1 to 100. The third dataset uses a mixture of both linearly and
non-linearly separable biomarkers. Each of these datasets is also varied by increasing
noise level. For example, the datasets with linearly separable noise have either 10%
or 30% overlap between class 1 and class 2 distributions (Figure 15, rows one and
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Table 4: One-dimensional Gaussian distribution means for relevant and irrelevant
feature sets in the synthetic datasets. Standard deviations of Gaussian distributions
are one.
Group Feature Set Class 1 Class 2
Label Group Mean Mean
A Diff. Exp. Linear 10% Overlap -1.2816 1.2816
B Diff. Exp. Linear 30% Overlap -0.5244 0.5244
C Diff. Exp. Non-Linear 10% Overlap ± 2.5632 0
D Diff. Exp. Non-Linear 30% Overlap ± 1.0488 0
E No Diff. Exp. 100% Overlap 0 0
two). Feature sets in each class are modeled as simple Gaussian distributions. Like-
wise, the synthetic datasets with two-dimensional feature sets are two-dimensional
Gaussian distributions with 10% or 30% overlap (Figure 16, top row). Non-linearly
separable feature sets are modeled as combinations of Gaussian distributions such
that the classes cannot be optimally separated using a linear hyperplane (Figure
15, rows three and four, Figure 16, bottom row). By varying the noise level of
the linear and non-linear datasets, we can assess the robustness of ranking metric
optimization to variations in the distribution of differentially expressed feature sets.
However, because differentially expressed feature sets in a clinical dataset are seldom
similarly distributed, we also use a synthetic dataset of mixed distributions to test
the robustness of this method to heterogeneous data.
4.2.7 Microarray Data Analysis and qRT-PCR Validation
We examine four clinical endpoints using various cancer microarray datasets: renal,
prostate, and breast cancer. The renal cancer data includes two clinical endpoints and
each of the prostate and breast cancer datasets include one endpoint. Furthermore,
we use two independent microarray datasets for each endpoint. Table 7 summarizes
the clinical data endpoints.
The renal cancer datasets are derived from two independent studies. The first
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Table 5: Two-dimensional Gaussian distribution means for relevant and irrelevant
feature sets in the synthetic dataset. Standard deviations of Gaussian distributions
are one.
Group Feature Set Class 1 Class 2
Label Group Mean Mean
A Diff. Exp. Linear 10% Overlap x: -0.9062 x: 0.9062
y: -0.9062 y: 0.9062
B Diff. Exp. Linear 30% Overlap x: -0.3708 x: 0.3708
y: -0.3708 y: 0.3708
C Diff. Exp. Non-Linear 10% Overlap x: ∓ 1.2816 x: ∓ 1.2816
y: ∓ 1.2816 y: ± 1.2816
D Diff. Exp. Non-Linear 30% Overlap x: ∓ 0.5244 x: ∓ 0.5244
y: ∓ 0.5244 y: ± 0.5244
E No Diff. Exp. 100% Overlap 0 0
Table 6: Distribution of feature sets for synthetic data.
Feature Set Linear Linear Non-linear Non-linear Mixed Mixed
Number 10% 30% 10% 30% 10% 30%
1-50 A B C D A B
50-100 A B C D C D
101-3000 E E E E E E
Table 7: Clinical microarray datasets for knowledge-guided biomarker identification.
For each end point, we use two microarray datasets to examine the effect of knowledge-
guided feature selection. Each dataset varies in terms of clinical endpoint as well
as sample size. Knowledge genes used to assess biomarker detection efficiency are
identified from literature as well as from qRT-PCR experiments.
Dataset Endpoint # Knowledge Endpoint Dataset 1 Dataset 2












52 50 61 63
Norm. Adj. Tissue
Breast D 8 pCR vs RD 21 60 12 37
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Distribution of Synthetic Gene Expression






















































Figure 15: One-Dimensional Synthetic Gene Expression Data Distributions. Each
class distribution is Gaussian with variance of one. Linearly separable with 10%
overlap between classes (top row). Linearly separable with 30% overlap between
classes (second row). Non-linearly separable with 10% overlap between classes (third
row). Non-linearly separable with 30% overlap between classes (bottom row).
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Figure 16: Two-Dimensional Synthetic Gene Expression Data Distributions. Circles
represent Gaussian distributions with variance of one. Linearly separable with 10%
overlap between classes (top left). Linearly separable with 30% overlap between
classes (top right). Non-linearly separable with 10% overlap between classes (bottom
left). Non-linearly separable with 30% overlap between classes.
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dataset, from a study by Schuetz et al., uses Affymetrix microarrays (HG-Focus,
8793 probesets) to profile samples from several subtypes of renal tumors: 13 clear cell
(CC) renal cell carcinoma (RCC), 4 chromophobe (CHR) RCC, and 3 oncocytoma
(ONC, benign), and 5 papillary (PAP) [124]. The second dataset, from a study by
Jones et al., uses a different model of Affymetrix microarrays (HG-U133A, 22283
probesets reduced to 8793 that are common to HG-Focus) to examine similar renal
tumor subtypes with 32 CC, 6 CHR, 12 ONC samples, and 11 PAP [67]. We are
interested in biomarkers that differentiate the CC class from the combined group of
ONC and CHR (endpoint A) as well as biomarkers that differentiate the CC class
from the PAP class (endpoint B).
The prostate cancer datasets are derived from independent studies identifying
biomarkers that can differentiate tumor tissue from normal prostate tissue adjacent
to tumors [133, 19]. Both of these studies use Affymetrix HG-U95Av2 microarrays and
have a relatively large number of samples and probesets compared to the renal cancer
endpoints. The breast cancer datasets are derived from a study that focuses on iden-
tifying biomarkers that can identify patients most likely to respond to chemotherapy
[53]. These datasets were assayed on Affymetrix HG-U133A microarrays and contain
22283 probesets.
Using literature, we identify genes that have been validated (via qRT-PCR or
IHC) as differentially expressed between the disease/patient groups for each of the
clinical endpoints. We then validate an additional 94 genes using qRT-PCR (using
RNA from 34 CC and 18 CHR tissue samples) for the renal cancer endpoints. These
94 genes were selected by a renal cancer pathologist based on his knowledge and pre-
vious research. Only some of the 94 genes assayed with qRT-PCR are differentially
expressed in the two clinical scenarios as assessed by a linear SVM with classification
error estimated using 0.632 bootstrap. Genes measured with qRT-PCR are catego-
rized as differentially expressed if the estimated classification error is less than 10%
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(or 20% in the case of the CC vs PAP comparison). Using the set of knowledge from
both literature and qRT-PCR validation, we examine the efficiency of detecting these
biomarkers for each clinical endpoint by optimizing the ranking metric under various
conditions, as illustrated in Figure 14.
4.3 Results and Discussion
4.3.1 Synthetic Data Simulations
In most cases, when using the maximum likelihood approach, optimizing the ranking
metric improves the efficiency of detecting differentially expressed feature sets in
synthetic data (Figure 17, Figure 18, Figure 19, Figure 20, Figure 21, and
Figure 22). In each of these figures, the solid black line is the detection-efficiency
curve for the optimally selected ranking metric. This line is an average of 100 curves,
each of which is generated by a bootstrap iteration (described in the previous section).
The dashed line indicates the standard deviation of the 100 iterations. The box plots
represent the area under the curve (AUC) and summarize the performance of feature
set detection (‘O’ = optimal, ‘SO’ = sub-optimal, and ‘SK’ = sub-optimal initial
knowledge). We also examine the effect of increasing noise (results of 10% noise are
in first column of each figure and results for 30% are in the second column). In all
cases, the optimal algorithm performs very well in low noise scenarios. Performance
decreases when we increase data noise to 30%, most notably in the non-linear one-
and two- dimensional cases (Figure 18(b), Figure 21(b)). Obviously, the larger
noise level increases the difficulty of detecting differentially expressed feature sets in
general, especially in such small datasets. Thus, increasing the synthetic data sample
size from 10 samples per class to 20 samples per class improves detection efficiency
(Figure 17(c), Figure 18(c), Figure 19(c), Figure 20(c), Figure 21(c), and
Figure 22(c)).
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As expected, choosing a sub-optimal ranking metric reduces the efficiency of de-
tecting differentially expressed feature sets, as indicated by a decrease in the AUCs
(red line). Using sub-optimal initial knowledge also decreases the efficiency of detect-
ing these feature sets, but it also significantly increases the variance of the detection
curves (blue line). This result is consistent among all synthetic datasets. In some
cases, the sub-optimal initial knowledge simulation initially performs worse than the
sub-optimal simulation, but improves as the simulation progresses. This may be ex-
plained by the iterative addition of truly differentially expressed feature sets to the
knowledge set. Thus, even if we begin with a poor set of prior knowledge, if we
perform enough validations to progressively improve the knowledge set, then valida-
tion efficiency will increase. When ranking feature sets using a sub-optimal ranking
metric or sub-optimal initial knowledge, we can expect an increase in the false dis-
covery rate. Translating to a clinical scenario, because validation requires time and
resources, we should expect that an increase in the false discovery rate would also
reduce the efficiency of biomarker validation.
Finally, optimizing the ranking metric using a mixture of linearly and non-linearly
separable feature sets does not decrease the effect of optimization (Figure 19, Figure
22). In these cases, because the initial knowledge set contains both linearly and non-
linearly separable feature sets, we can assume that the optimization process identifies
a metric that can adequately identify both types of feature sets.
The box plots of each figure also include control cases in which we use randomly
selected knowledge from the feature sets that are not differentially expressed. These
box plots are labeled with ‘CO’ = control optimal, ‘CSO’ = control sub-optimal, and
‘CSK’ = control sub-optimal initial knowledge. As expected the AUCs of each of
these controls are close to 0.5.
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(a) Synthetic one-dimensional linearly separable data simulations with 10% class overlap and 10 sam-
ples per class.
Figure 17: The optimally selected ranking metric (black line) is more efficient in
detecting differentially expressed feature sets compared to the sub-optimal metrics
(blue and red lines). This is true for the low noise case (17(a)), high noise case
(17(b), next page), and high noise case with larger sample size (17(c), next page).
The left figures contain box plots of the area under the ROC curve for the three
simulations-optimal algorithm (O), sub-optimal algorithm (SO), and sub-optimal ini-
tial knowledge (SK)-as well as three control cases in which knowledge was randomly
selected (CO, CSO, and CSK). The control tests show that choice of knowledge is im-
portant. Noise generally increases the difficulty of identifying differentially expressed
genes (17(b), next page), even with the introduction of prior knowledge. However,
increasing the sample size reduces the false discovery rate, resulting in a higher AUC
for the optimal algorithm (17(c), next page).
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(b) Synthetic one-dimensional linearly separable data simulations with 30% class overlap and 10 sam-
ples per class.











Efficiency of Biomarker Detection
Synthetic Linear 1D Data, 30% Class Overlap, 20 Samples/Class
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(c) Synthetic one-dimensional linearly separable data simulations with 30% class overlap and 20 samples
per class.
Figure 17 parts (b) and (c). Figure part (a) and full caption on the previ-
ous page.
65











Efficiency of Biomarker Detection
Synthetic Nonlinear 1D Data, 10% Class Overlap, 10 Samples/Class



























Efficiency of Biomarker Detection












(a) Synthetic one-dimensional non-linearly separable data simulations with 10% class overlap and 10
samples per class.
Figure 18: Synthetic one-dimensional non-linearly separable data simulations with
varying noise levels and sample size. Similar to the linearly separable case, the opti-
mally selected ranking metric (black line) for the non-linearly separable case is more
efficient in detecting differentially expressed feature sets compared to the sub-optimal
metrics (blue and red lines). However, as noise increases, the false discovery rate also
increases significantly (18(b), next page). Again, the addition of samples reduces the
false discovery rate (18(c), next page). The left figures contain box plots of the area
under the ROC curve for the three simulations-optimal algorithm (O), sub-optimal
algorithm (SO), and sub-optimal initial knowledge (SK)-as well as three control cases
in which knowledge was randomly selected (CO, CSO, and CSK). The control tests
show that choice of knowledge is important.
66











Efficiency of Biomarker Detection
Synthetic Nonlinear 1D Data, 30% Class Overlap, 10 Samples/Class



























Efficiency of Biomarker Detection












(b) Synthetic one-dimensional non-linearly separable data simulations with 30% class overlap and 10
samples per class.











Efficiency of Biomarker Detection
Synthetic Nonlinear 1D Data, 30% Class Overlap, 20 Samples/Class
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(c) Synthetic one-dimensional non-linearly separable data simulations with 30% class overlap and 20
samples per class.
Figure 18 parts (b) and (c). Figure part (a) and full caption on the previ-
ous page.
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(a) Synthetic one-dimensional mixed data simulations with 10% class overlap and 10 samples per class.
Figure 19: Synthetic one-dimensional mixed data simulations with varying noise
levels and sample size. Mixed data consists of both linearly and non-linearly sepa-
rable biomarkers. Similar to the linearly and non-linearly separable cases, the op-
timally selected ranking metric (black line) for the mixed case is more efficient in
detecting differentially expressed feature sets compared to the sub-optimal metrics
(blue and red lines). Once again, increases in noise increases the false discovery rate
(19(b), next page), but addition of samples decreases the false discovery rate (19(c),
next page). The top row contains box plots of the area under the ROC curve for
the three simulations-optimal algorithm (O), sub-optimal algorithm (SO), and sub-
optimal initial knowledge (SK)-as well as three control cases in which knowledge was
randomly selected (CO, CSO, and CSK). The control tests show that choice of knowl-
edge is important. This simulation shows that, even in the presence of a mixture of
biomarker distributions, a diverse population of feature selection methods will still
yield a method that performs well.
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(b) Synthetic one-dimensional mixed data simulations with 30% class overlap and 10 samples per class.











Efficiency of Biomarker Detection
Synthetic Mixed 1D Data, 30% Class Overlap, 20 Samples/Class
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(c) Synthetic one-dimensional mixed data simulations with 30% class overlap and 20 samples per class.
Figure 19 parts (b) and (c). Figure part (a) and full caption on the previ-
ous page.
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(a) Synthetic two-dimensional linearly separable data simulations with 10% class overlap and 10 sam-
ples per class.
Figure 20: Synthetic two-dimensional linearly separable data simulations with vary-
ing noise levels and sample size. The optimally selected ranking metric (black line) is
more efficient in detecting differentially expressed feature sets compared to the sub-
optimal metrics (blue and red lines). This is true for the low noise case (20(a)), high
noise case (20(b), next page), and high noise case with larger sample size (20(c),
next page). The left figures contain box plots of the area under the ROC curve for
the three simulations-optimal algorithm (O), sub-optimal algorithm (SO), and sub-
optimal initial knowledge (SK)-as well as three control cases in which knowledge was
randomly selected (CO, CSO, and CSK). The control tests show that choice of knowl-
edge is important. Noise generally increases the difficulty of identifying differentially
expressed genes (middle column), even with the introduction of prior knowledge.
However, increasing the sample size reduces the false discovery rate, resulting in a
higher AUC for the optimal algorithm (20(c), next page).
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(b) Synthetic two-dimensional linearly separable data simulations with 30% class overlap and 10 sam-
ples per class.
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(c) Synthetic two-dimensional linearly separable data simulations with 30% class overlap and 20 sam-
ples per class.
Figure 20 parts (b) and (c). Figure part (a) and full caption on the previ-
ous page.
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(a) Synthetic two-dimensional non-linearly separable data simulations with 10% class overlap and 10
samples per class.
Figure 21: Synthetic two-dimensional non-linearly separable data simulations with
varying noise levels and sample size. Similar to the linearly separable case, the opti-
mally selected ranking metric (black line) for the non-linearly separable case is more
efficient in detecting differentially expressed feature sets compared to the sub-optimal
metrics (blue and red lines). However, as noise increases, the false discovery rate also
increases significantly (21(b), next page). Again, the addition of samples reduces the
false discovery rate (21(c), next page). The top row contains box plots of the area
under the ROC curve for the three simulations-optimal algorithm (O), sub-optimal
algorithm (SO), and sub-optimal initial knowledge (SK)-as well as three control cases
in which knowledge was randomly selected (CO, CSO, and CSK). The control tests
show that choice of knowledge is important.
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(b) Synthetic two-dimensional non-linearly separable data simulations with 30% class overlap and 10
samples per class.
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(c) Synthetic two-dimensional non-linearly separable data simulations with 30% class overlap and 20
samples per class.
Figure 21 parts (b) and (c). Figure part (a) and full caption on the previ-
ous page.
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(a) Synthetic two-dimensional mixed data simulations with 10% class overlap and 10 samples per class.
Figure 22: Synthetic two-dimensional mixed data simulations with varying noise
levels and sample size. Mixed data consists of both linearly and non-linearly sepa-
rable biomarkers. Similar to the linearly and non-linearly separable cases, the op-
timally selected ranking metric (black line) for the mixed case is more efficient in
detecting differentially expressed feature sets compared to the sub-optimal metrics
(blue and red lines). Once again, increases in noise increases the false discovery rate
(22(b), next page), but additional samples decreases the false discovery rate (22(c),
next page). The top row contains box plots of the area under the ROC curve for
the three simulations-optimal algorithm (O), sub-optimal algorithm (SO), and sub-
optimal initial knowledge (SK)-as well as three control cases in which knowledge was
randomly selected (CO, CSO, and CSK). The control tests show that choice of knowl-
edge is important. This simulation shows that, even in the presence of a mixture of
biomarker distributions, a diverse population of feature selection methods will still
yield a method that performs well.
74











Efficiency of Biomarker Detection
Synthetic Mixed 2D Data, 30% Class Overlap, 10 Samples/Class



























Efficiency of Biomarker Detection












(b) Synthetic two-dimensional mixed data simulations with 30% class overlap and 10 samples per class.
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(c) Synthetic two-dimensional mixed data simulations with 30% class overlap and 20 samples per class.
Figure 22 parts (b) and (c). Figure part (a) and full caption on the previ-
ous page.
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4.3.2 Clinical Data Analysis
As described in the methods, we identify several biomarkers from literature that are
differentially expressed for each of the four clinical endpoints. For endpoints A and
B, the renal cancer endpoints, we identified additional biomarkers using qRT-PCR
validation. Table 8 lists the renal cancer biomarkers identified from literature for end-
points A1 and A2. qRT-PCR validated biomarkers for endpoints A and B are listed
in Table 9 and Table 10, respectively. We filter the qRT-PCR validated biomark-
ers such that their estimated classification errors are less than 10%. Biomarker for
prostate and breast cancer are more difficult to identify, mainly due to the heterogene-
ity of these diseases. The MYC and FASN (fatty acid synthase) genes are differentially
expressed in normal and prostate cancer tissue as assessed by immunohistochemistry
[110]. Schlomm et al. also identified and validated MYC as well as FOLH1 using
qRT-PCR [122]. Hepsin (HPN), AMACR, and SARDH have also been validated us-
ing various methods [136, 85, 121]. These biomarkers are listed in Table 11. It is
important that the biomarkers used as knowledge to guide feature selection be specific
to the disease in question. For example, biomarkers that are differentially expressed
between metastatic prostate cancer and benign prostate cancer may not be appropri-
ate for distinguishing prostate tumors from normal tissue. Likewise, we identify the
MAPT and KI67 biomarkers from literature that are differentially expressed between
breast cancer treatment success and failure (Table 12). Using immunohistochem-
istry, Rouzier et al. identified and validated the microtubule-associated protein tau
(MAPT) as a biomarker for paclitaxel (chemotherapy) sensitivity in breast cancer
[120]. The Ki-67 biomarker was shown to have a strong correlation with pathologi-
cal response to chemotherapy in breast cancer patients [15]. Because of the variety
of chemotherapy regimens for breast cancer, knowledge biomarkers should be care-
fully chosen to closely reflect the dataset of interest. Here, we examine the pathologic
76
response of breast cancer patients to a common treatment regimen, T/FAC. Biomark-
ers that can predict success or failure to this particular treatment regimen may not
accurately predict success or failure for a different treatment regimen.
Combining all knowledge from both literature and qRT-PCR validation, we exam-
ine the effect of optimizing the feature ranking metric using the method illustrated in
Figure 14. For the CC vs ONC/CHR subtype comparison, endpoints A1 and A2, box
plots of the 100 iterations for each of the three tests indicate that knowledge guided
feature selection method using both MLE and MAP (black lines) outperforms the
standard significance analysis of microarrays (SAM, green line) filter method (Figure
23). The Bayesian maximum a posteriori method (solid line) slightly outperforms
the MLE method (dashed line) when the initial knowledge is of good quality. In the
scenario where the initial knowledge is randomly selected from the set of all genes,
the MAP method significantly outperforms the MLE method (red lines). The box
plots (Figure 23, left column) represent the median and quartiles of the AUC values
for each of the 100 iterations. The results are similar for the renal cancer endpoints
B1 and B2, although the improvement from using the Bayesian MAP approach for
endpoint B2 is not significant (Figure 24). As expected, the control tests, in which
we are detecting randomly selected genes using randomly selected initial knowledge,
result in AUCs of approximately 0.5. This indicates that none of the feature selection
methods favors uninformative genes better than random chance.
For the prostate cancer endpoints, C1 and C2, the knowledge-guide biomarker
identification algorithm appears to be less efficient compared to SAM (Figure 25).
This result may seem unintuitive since the SAM method is included in the population
of feature selection methods that the knowledge-guided algorithm considers. If we
were to consider all knowledge genes identified for the prostate cancer endpoints in
Table 11, the best method would likely be SAM. However, due to the bootstrapping
that occurs in the simulation, only a subset of the knowledge genes are considered
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for selecting the best algorithm. Therefore, the resulting decrease in detection per-
formance is likely due to the fact that the knowledge set only contains a relatively
small number of genes and that these genes may not be representative of the best
biomarkers for this particular clinical endpoint. Nevertheless, we still see relatively
good performance of the knowledge-guided biomarker detection algorithm compared
to the sub-optimal initial knowledge simulation. Again, there is a slight improve-
ment of the Bayesian MAP method for the sub-optimal initial knowledge simulation,
although the improvement is not statistically significant.
Results are similar for the breast cancer endpoints, D1 and D2, (Figure 26).
In this simulation, we see that the knowledge-guided biomarker detection algorithm
performs better than fold change filtering for the D1 endpoint and similarly for the
D2 endpoint. Again, we see that the Bayesian MAP method improves detection
efficiency, especially for the sub-optimal initial knowledge simulations (red lines).
The high variance of the suboptimal initial knowledge condition indicates that
optimization of the ranking metric is sensitive to the initial conditions. Some of the
randomly selected initial knowledge may, in fact, be differentially expressed, resulting
in good performance. However, these random initial knowledge sets are more likely to
be irrelevant. Thus, box plots for this condition illustrate this mixture of knowledge
quality. These results stress the importance of the quality of biomarker knowledge.
Table 8: Genes identified from literature as differentially expressed between renal
cancer CC and ONC/CHR subtypes.
Gene Symbol Knowledge Source Validation Method
CA9 Chen, Clin Cancer Res, 2005 qRT-PCR
CLCNKB Chen, Clin Cancer Res, 2005 qRT-PCR
DEFB1 Schuetz, J Mol Diagn, 2005 qRT-PCR, IHC
LRP2 Schuetz, J Mol Diagn, 2005 qRT-PCR, IHC
PVALB Chen, Clin Cancer Res, 2005 qRT-PCR
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Table 9: Genes validated with qRT-PCR for the renal cancer CC vs ONC/CHR
subtype comparison. These genes have estimated classification errors of less than
10% as assessed by a linear SVM classifier using 0.632 bootstrap estimation.

















Table 10: Genes validated with qRT-PCR for the renal cancer CC vs PAP subtype
comparison. These genes have estimated classification errors of less than 20% as
assessed by a linear SVM classifier using 0.632 bootstrap estimation.














Table 11: Validated prostate cancer biomarkers identified from literature. These
biomarkers are specific for distinguishing prostate tumor samples from normal
prostate tissue.
Gene Symbol Source
SARDH Sreekumar, Nature, 2009
AMACR Luo, Cancer Research, 2002
HPN Sardana, Clin Chem, 2008
MYC Prowatke, British Journal of Cancer, 2007
FASN Prowatke, British Journal of Cancer, 2007
FOLH1 Schlomm, Eur Urol, 2008
Table 12: Validated breast cancer biomarkers identified from literature. These
biomarkers are specific for distinguishing between chemotherapy treatment outcome.
Specifically, for pathologic complete response (pCR) to T/FAC treatment versus resid-
ual disease after a predefined period of time.
Gene Symbol Source
MAPT Rouzier, PNAS, 2005



















Biomarker Detection Efficiency, Endpoint A1
Renal Cancer CC vs ONC/CHR
p=2.4e−10



























Biomarker Detection Efficiency, Endpoint A1



























Biomarker Detection Efficiency, Endpoint A2
Renal Cancer CC vs ONC/CHR
p=5.3e−5



























Biomarker Detection Efficiency, Endpoint A2










Figure 23: Biomarker detection efficiency assessed for data endpoints A1 and A2,
renal cancer CC vs ONC/CHR. The detection efficiency curves (right column) rep-
resent average biomarker detection efficiency over 100 bootstrap iterations. Black
lines represent optimal ranking metric selection using either the maximum likelihood
(MLE, dashed lines) or Bayesian maximum a posteriori (MAP, solid lines) methods.
Optimal ranking metric selection performs better when the initial knowledge is cor-
rect, compared to the case in which the initial knowledge is randomly chosen (red
lines). Control tests (blue lines) indicate cases in which all knowledge genes are ran-
domly chosen. As a baseline comparison, we plot the biomarker detection efficiency
of SAM, a standard gene filtering method. Overall, SAM performs slightly worse
compared to the adaptive knowledge based biomarker detection. The figures in the
left column are box plots of area under the curve (AUC) for each of the detection
efficiency curves. The Bayesian MAP method performs significantly better than MLE



















Biomarker Detection Efficiency, Endpoint B1
Renal Cancer CC vs PAP
p=0.0014
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Biomarker Detection Efficiency, Endpoint B2
Renal Cancer CC vs PAP
p=0.9754



























Biomarker Detection Efficiency, Endpoint B2










Figure 24: Biomarker detection efficiency assessed for data endpoints B1 and B2,
renal cancer CC vs PAP. The detection efficiency curves (right column) represent
average biomarker detection efficiency over 100 bootstrap iterations. Black lines rep-
resent optimal ranking metric selection using either the maximum likelihood (MLE,
dashed lines) or Bayesian maximum a posteriori (MAP, solid lines) methods. Opti-
mal ranking metric selection performs better when the initial knowledge is correct,
compared to the case in which the initial knowledge is randomly chosen (red lines).
Control tests (blue lines) indicate cases in which all knowledge genes are randomly
chosen. As a baseline comparison, we plot the biomarker detection efficiency of SAM,
a standard gene filtering method. Overall, SAM performs slightly worse compared to
the adaptive knowledge based biomarker detection. The figures in the left column are
box plots of area under the curve (AUC) for each of the detection efficiency curves.
The Bayesian MAP method performs significantly better than MLE in sub-optimal
initial knowledge conditions for the B1 endpoint. Bayesian MAP is nominally better



















Biomarker Detection Efficiency, Endpoint C1
Prostate Cancer Tumor vs Normal Adjacent
p=0.381
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Biomarker Detection Efficiency, Endpoint C2
Prostate Cancer Tumor vs Normal Adjacent 
p=0.245
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Figure 25: Biomarker detection efficiency assessed for data endpoints C1 and C2,
prostate cancer tumor vs normal adjacent tissue. The detection efficiency curves
(right column) represent average biomarker detection efficiency over 100 bootstrap
iterations. Black lines represent optimal ranking metric selection using either the
maximum likelihood (MLE, dashed lines) or Bayesian maximum a posteriori (MAP,
solid lines) methods. Optimal ranking metric selection performs better when the
initial knowledge is correct, compared to the case in which the initial knowledge
is randomly chosen (red lines). Control tests (blue lines) indicate cases in which
all knowledge genes are randomly chosen. As a baseline comparison, we plot the
biomarker detection efficiency of SAM, a standard gene filtering method. Overall,
SAM performs slightly better compared to the adaptive knowledge based biomarker
detection. The figures in the left column are box plots of area under the curve (AUC)
for each of the detection efficiency curves. The Bayesian MAP method performs
slightly better than MLE in sub-optimal initial knowledge conditions for both the C1



















Biomarker Detection Efficiency, Endpoint D1
Breast Cancer pCR vs RD
p=0.084
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Biomarker Detection Efficiency, Endpoint D2
Breast Cancer pCR vs RD
p=0.224
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Figure 26: Biomarker detection efficiency assessed for data endpoints D1 and D2,
breast cancer pCR vs RD (treatment outcome). The detection efficiency curves (right
column) represent average biomarker detection efficiency over 100 bootstrap itera-
tions. Black lines represent optimal ranking metric selection using either the maxi-
mum likelihood (MLE, dashed lines) or Bayesian maximum a posteriori (MAP, solid
lines) methods. Optimal ranking metric selection performs better when the initial
knowledge is correct, compared to the case in which the initial knowledge is randomly
chosen (red lines). Control tests (blue lines) indicate cases in which all knowledge
genes are randomly chosen. As a baseline comparison, we plot the biomarker detection
efficiency of the commonly used fold-change ranking method. Overall, fold change
performs almost equally compared to the adaptive knowledge based biomarker detec-
tion. The figures in the left column are box plots of area under the curve (AUC) for
each of the detection efficiency curves. The Bayesian MAP method performs slightly
better than MLE in sub-optimal initial knowledge conditions for both the D1 and D2
endpoints, but the difference is not statistically significant for endpoint D2.
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4.3.3 Evolution of Ranking Algorithm Probabilities
During the biomarker discovery process, as we introduce knowledge, the biological
relevance–or probability–of each ranking algorithm changes. The iterative changes
reflect our changing knowledge about the clinical problem. Moreover, as the prob-
abilities change, the resulting optimal ranking algorithm should also change. We
expect that the probabilities are highly variable when our knowledge is small, but
evolves toward the true solution as knowledge increases. Iterative identification of
new and validated biomarkers using the maximum likelihood algorithm or the maxi-
mum a posteriori approach should result in very different changes to the probabilities.
Here, we examine the differences between these two methods using the renal cancer
dataset that compares CC and ONC/CHR subtypes (endpoints A1 and A2). We use
the identified and validated biomarkers for this dataset (Table 8, Table 9) and the
bootstrap method described in the previous section. The probabilities update after
discovering each new biomarker. We also use the sub-optimal initial knowledge case
to determine which probability update method is more effective.
Figure 27 is the evolution of ranking algorithm probabilities using the maximum
likelihood algorithm. From the initial knowledge set (Figure 27(a)) to the final iter-
ation after adding approximately 10 new biomarkers as additional knowledge (Figure
27(c)) does not significantly change the algorithm probabilities. However, the algo-
rithm with maximum likelihood changes slightly. The contrast in color within the
space SVM RBF ranking algorithms indicates the contrast in biological relevance of
the methods (27, left panels). It is difficult to gauge the benefit of additional knowl-
edge in this scenario due to the very small changes in the algorithm probabilities. As
such, we also examine the scenario in which the initial knowledge is of poor quality–
i.e., we begin with a knowledge set that includes several randomly selected genes that
have not been validated and will likely not be favorably ranked by any ranking metric
(Figure 28). In contrast to the scenario with correct initial knowledge, the algorithm
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probabilities initialized using the randomly selected knowledge does not have distinct
regions of biological relevance. In other words, there is not a set of feature ranking
metrics that appear to stand out as the most biologically relevant given the initial
knowledge. This implies that, as expected, none of the ranking metrics can correctly
identify the initial biomarkers. As we detect and validate new biomarkers, the algo-
rithm probabilities begin to form distinct regions that correspond to those in Figure
27.
Figure 29 is an example of the evolution of ranking metric probabilities when
we introduce knowledge and update probabilities using the maximum a posteriori
approach. The probabilities displayed in the first (Figure 29(a)), fifth (Figure
29(b)), and tenth (Figure 29(c)) iterations are posterior probabilities. The regions
that emerge as the most biologically relevant are similar to those of the maximum
likelihood method (Figure 27). However, we also see that regions of the linear SVM
parameter space as well as the fold change and SAM methods also emerge as more
biologically relevant compared to other feature ranking metrics. Despite incorrect
initial knowledge, the maximum a posteriori approach to ranking metric selection
still efficiently identifies biologically relevant regions of the parameter space within a
few iterations (Figure 30).
Figure 31 and Figure 32 are further illustrations of the advantage of using the
Bayesian algorithm selection method in situations where initial knowledge may not
be reliable. Although the maximum likelihood algorithm identifies a few regions of
higher biological relevance, these regions are not distinctly different from other re-
gions. In contrast, the Bayesian selection method not only identifies these regions, but





















































































































Linear Classifiers and Filters












































































































Linear Classifiers and Filters















































































































Linear Classifiers and Filters
(c) Iteration 10, Maximum Likelihood, Initial Knowledge +10 Validated Biomarkers
Figure 27: Evolution of ranking metric probabilities using the maximum likelihood
algorithm. There is very little difference between the iteration 1 (27(a)), iteration 5
(27(b)), and iteration 10 (27(c)) iteration as new knowledge is added. However, the
“optimal”, or algorithm with maximum likelihood changes slightly (black X) within
the space of SVM radial basis wrapper-based feature selection methods (left panel).
Probabilities of common filter-based feature selection methods (right panel: T-test,




















































































































Linear Classifiers and Filters
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Linear Classifiers and Filters
(c) Iteration 10, Maximum Likelihood, Random Initial Knowledge +10 Validated Biomarkers
Figure 28: Evolution of ranking metric probabilities using the maximum likelihood
algorithm with incorrect initial knowledge. Beginning with randomly selected ini-
tial knowledge, there is very little distinction between the different ranking metrics
(28(a)). As knowledge accumulates, resulting in a mixture of incorrect and correct
knowledge, some of the ranking metrics emerge and distinguish themselves from other
metrics in terms of biological relevance after 10 iterations (28(c)). Probabilities of
common filter-based feature selection methods (right panel: T-test, fold change, and
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Linear Classifiers and Filters
(c) Iteration 10, Maximum A Posteriori, Initial Knowledge +10 Validated Biomarkers
Figure 29: Evolution of the posterior probability of ranking metrics as knowledge
is introduced. The space of ranking metrics considered here include the radial basis
SVM (left panel), linear SVM (middle panel, top row), radial basis SDF (middle
panel, middle row), radial basis linear discriminant (LDA, middle panel, bottom
row), and linear SDF, linear LDA, and common filtering methods. Beginning with
initial knowledge (29(a)) to 10 iterations (29(c)), the maximum a posteriori method










































































































Linear Classifiers and Filters
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Linear Classifiers and Filters
(c) Iteration 10, Maximum A Posteriori, Random Initial Knowledge +10 Validated Biomarkers
Figure 30: Evolution of the posterior probability of ranking metrics as knowledge
is introduced and beginning with randomly selected initial knowledge. Despite the
incorrect initial knowledge, or prior, the maximum a posteriori method quickly iden-
tifies regions of biological relevance after 10 iterations (30(c)). The space of ranking
metrics considered here include the radial basis SVM (left panel), linear SVM (mid-
dle panel, top row), radial basis SDF (middle panel, middle row), radial basis linear































(a) SVM ranking metric probability surface after 1 iteration of the maximum
likelihood method using random initial knowledge.
Figure 31: Evolution of the probability surface of the radial basis SVM ranking met-
rics using the maximum likelihood method and randomly selected initial knowledge.
Some regions appear as more biologically relevant but are not significantly more so
than the other regions. There is very little difference between probability surfaces































(b) SVM ranking metric probability surface after 5 iterations of the maximum





























(c) SVM ranking metric probability surface after 10 iterations of the maximum
likelihood method using random initial knowledge.






























(a) SVM ranking metric probability surface after 1 iteration of the maximum a
posteriori method using random initial knowledge.
Figure 32: Evolution of the radial basis SVM probability surface using the maximum
a posteriori algorithm and randomly selected initial knowledge. Within 10 iterations
(iteration 1 (32(a)), iteration 5 (32(b), next page), and iteration 10 (32(c), next































(b) SVM ranking metric probability surface after 5 iterations of the maximum a





























(c) SVM ranking metric probability surface after 10 iterations of the maximum a
posteriori method using random initial knowledge.
Figure 32 parts (b) and (c). Figure part (a) and full caption on the previous page.
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4.3.4 Identifying and Validating Novel Biomarkers
Using all knowledge from literature and the first round of qRT-PCR for the CC and
ONC/CHR comparison (endpoint A1 and A2), we optimize the ranking metric and
select the top genes that have not been previously validated and that have estimated
classification errors of less than 5% (Table 13). We can link a few of these genes
directly to previous literature pertaining to renal cancer. For example, CXCR4 has
been linked to kidney cancer. Using qRT-PCR, Schrader et al. shows that this gene
is over-expressed in kidney cancer tissue compared to normal kidney tissue [123].
IGFBP3 and KLF10 have also been linked to renal cell carcinoma [117, 65]. Validation
of these genes using qRT-PCR may yield additional knowledge to iteratively refine
the biomarker selection process. However, since we want to primarily focus on the
methodology here, we reserve the actual validation of these results for a future study.
Table 13: Proposed list of renal cancer genes for further qRT-PCR validation.




















We have shown that biomarker identification by feature ranking benefits from knowl-
edge integration at key points. Using this knowledge–whether from clinical obser-
vations, laboratory experiments, or existing literature–we can intelligently choose an
optimal ranking metric for a specific gene expression dataset. The use of an opti-
mal metric for ranking and identifying novel biomarkers reduces the number of false
discoveries, increases the number of true discoveries, reduces the required time for val-
idation, and increases the overall efficiency of the process. There are two methods for
integrating knowledge: maximum likelihood and maximum a posteriori estimation.
Both methods result in a similar increase in biomarker detection efficiency. However,
the Bayesian inference method tends to be more robust to noise due to less reliable
knowledge.
The results of our simulations indicate that knowledge integration improves biomarker
selection for clinical microarray data. Although this study assumes independent gene
expression, the method is general and we can use it to rank combinatorial gene ex-
pression data as well. Furthermore, we test this method using only a limited set of
wrapper-based feature ranking metrics and common filter methods such as the t-test,
fold change, and SAM. However, it is easily expandable to encompass a larger variety
of metrics. We hope that the proposed method will impact biomarker identification
practices and improve the effectiveness of resulting clinical applications.
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CHAPTER V
IMPROVING CLINICAL PREDICTION USING
BIOLOGICAL KNOWLEDGE
5.1 Introduction
We have seen that knowledge integration improves the biological relevance of feature
selection [106]. However, we also want to know if biological knowledge can improve
the accuracy of clinical prediction. Biomarker identification improves our understand-
ing of the underlying biological mechanisms of disease. But it is unclear whether the
biological relevance of a particular biomarker implies that it may also be used as an
accurate predictor. In this chapter, we perform a systematic study of clinical pre-
dictors to determine whether the integration of biological knowledge into the feature
selection process improves prediction performance.
The steps involved in building clinical predictors include (1) feature selection,
(2) prediction performance estimation, and (3) prediction performance evaluation on
external data. Step two is not necessary for building the final model. However, this
step is essential in order to assess the performance of a predictor on future samples.
The process of building a predictive model may be carried out from a purely data-
driven perspective, in which the biological relevance of the model–e.g., the features
selected for the model–is not verified. Indeed, such a perspective may result in a
wide variety of models that are not biologically related but perform equally well
(or equally poorly). We expect the variance in model performance to be greatly
affected by the feature selection method. In this study, we examine several feature
selection methods and compare some common filter-based methods to a method that
is knowledge-driven rather than purely data-driven. We hope to determine whether
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integrating biological knowledge in the feature selection step results in more consistent
and better performing predictive models.
Clinical predictors must be subject to heavy scrutiny before final application in
clinical practice. However, we can only determine the impact of a predictor after
acquiring an adequate number of patient samples and comparing prediction results
to final clinical outcomes. The ultimate recommendation of a classification model is
based on an estimate of future prediction performance. Unfortunately, this estimate
depends on a subset of the total patient population, which may lead to a biased
estimate. Biased estimates are generally optimistic due to data over-fitting–i.e., the
prediction model becomes specialized to the patient sub-population and cannot gen-
eralize to the whole population. Thus, recommended models that are biased will
lead to poor prediction on future samples. Proper cross validation procedures on the




We build clinical predictive models from three different datasets using several feature
selection methods and classifiers (Table 14). The datasets include renal cancer,
prostate cancer, and breast cancer, each from public sources. We use two independent
datasets for each cancer in order to compute an unbiased estimate of predictive model
performance. The endpoint of a dataset refers to the specific medical condition we
wish to predict. For example, the clinical goal of endpoint A of the renal cancer data
is to develop a predictor that can classify patient samples into either the clear cell
carcinoma subtype or a combination of the oncocytoma and chromophobe subtypes.
Despite the very small sample size of one of the renal cancer datasets, we include
this dataset to assess the effect of small sample size on prediction performance. The
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Table 14: Clinical microarray datasets for knowledge-guided biomarker identifica-
tion. For each endpoint, we use two microarray datasets to examine the effect of
knowledge-guided feature selection. Each dataset varies in terms of clinical endpoint
as well as sample size. Knowledge genes used to assess biomarker detection efficiency
are identified from literature as well as from qRT-PCR experiments.
Dataset Endpoint # Knowledge Endpoint Dataset 1 Dataset 2












52 50 61 63
Norm. Adj. Tissue
Breast D 8 pCR vs RD 21 60 12 37
expected result is that the cross validation step will overestimate model performance.
We are also interested in the effect of knowledge integration on prediction performance
in small sample situations. The goal of endpoint B is to classify patients into the clear
cell and papillary subtypes [124, 67]. Endpoint C examines prostate cancer with the
goal of identifying molecular markers that can distinguish between prostate tumor and
normal adjacent tissue from the same patient [133, 19]. The prostate cancer datasets
have relatively large sample sizes compared to the renal cancer data. Endpoint D
examines breast cancer treatment outcomes. In the original study from which this
data was derived, the authors used two datasets to assess prediction accuracy of
several classifiers [53].
5.2.2 Estimating Predictive Performance Using Cross Validation
We build clinical predictors and assess their predictive performance using a full cross
validation procedure that is designed to mimic clinical scenarios in which the valida-
tion data is unknown or does not even exist during the training process. In clinical
practice, we hope to have a validated predictive model before receiving any new
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samples for classification. Consequently, the model building and selection procedure
should be completely separate from the validation procedure. In order to estimate
the performance of a potential predictor, we need to split the samples into training
and testing groups. All steps involved in determining the model–e.g. feature and pa-
rameter selection–should be applied to the training data. Once the model parameters
have been established, the model performance may be evaluated on the testing data.
The selection of samples for the training and testing data may also introduce a bias.
Therefore we recommended to create multiple partitions by using either cross valida-
tion or bootstrap. We use 10 iterations of stratified 5-fold cross validation. Within
each iteration, we compute and average five validation scores. We then compute the
average and standard deviation of the resulting 10 validation scores and use these
numbers as an estimate of model performance. Figure 33 is an example of this
process using 3-fold cross validation.
At this point, we have a performance estimate for each model via cross validation.
We then perform feature selection on the entire dataset and build a single classifier us-
ing these features. This classifier is tested on an external dataset whose samples were
never used during the cross validation process. Assuming that this external dataset
is similar to the original dataset, the estimated predictive performance computed us-
ing cross validation should be similar to the performance calculated from external
validation. The performance of the selected model should be high, but the ultimate
criterion of performance, of course, is that external validation is also accurate.
In terms of the microarray data, we perform full cross validation using datasets
A1, B1, C1, and D1 in order to estimate predictive performance. Using the same
modeling parameters as the cross validation step, we then apply these models to
train with the full A1, B1, C1, and D1 datasets and predict samples from the A2,
B2, C2, and D2 datasets. As such, each combination of modeling factors includes an
internal cross validation (CV) estimate of performance as well as an external “blind”
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validation (EV) score. We expect that the CV estimate and the EV score should be
comparable if the corresponding model does not over-fit to the training data. In order
to test the robustness of each model to changes in sample population, we swap the
training and testing data and repeat the cross validation and validation procedures.
For example, we perform full cross validation on the A2, B2, C2, and D2 datasets,
then validate these models using the A1, B1, C1, and D1 datasets.
5.2.3 Feature Selection and Biological Relevance
We test several feature selection methods, including the commonly used t-test, fold
change, and significance analysis of microarrays (SAM) [141]. Additionally, we also
test several wrapper based methods using the support vector machine (SVM), signed
distance function (SDF), and linear discriminant classifiers (LDA) [28, 6]. For each
classifier, we use the linear and radial basis kernel functions varied over several param-
eters (Table 15). We rank features by estimating their classification error using 100
iterations 0.632+ bootstrap [10, 37]. In total, we examine 258 different feature selec-
tion methods and vary feature sizes from 5 to 30 in steps of 5 (i.e., 5,10,15,20,25,30).
For each of the four datasets, we identify several previously validated biomarkers
for use as reference knowledge in order to assess the biological relevance of each
101
Ex: 3-Fold CV


















Mean of N 
Average Validation Scores
Standard Deviation of N 
Average Validation Scores
Figure 33: Assessing clinical predictor performance using full cross validation. In
order to compute an unbiased estimate of classifier performance on future data, we
need to perform a full cross validation in which all steps involved in the model building
process–feature selection and classifier parameter tuning–must be performed within
the cross validation.
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feature selection method. A feature selection method, θ, assigns to each gene, i, a
score based on its differential expression using a function hθ(~di), where ~di represents
expression values of the gene across all samples in the dataset and i = 1 . . .m. We
assume that lower ranking scores indicate higher differential expression and that all
scores are constrained to be within the interval [0,1]. We define Gk = {g1, g2, . . . , g3}
as the set of k relevant biomarkers such that elements of the set {hθ(~di) : i ∈ Gk} are
generally smaller than those of {hθ(~dj) : j ∈ Gk}. Then we can define the following








I(hθ(~di) < hθ(~dj)) (20)
where I(x) is the indicator function that evaluates to one when x is true and zero
when x is false. Equation 20 is equivalent to the area under an ROC curve [93].
This notation is similar to that used in a previous study that examined the biological
relevance of feature ranking [106]. We identify reference knowledge for each endpoint
using both literature and qRT-PCR validation (Table 16, Table 17, Table 18, and
Table 19).
5.2.4 Classifiers
We use three classifiers for both the wrapper-based feature selection methods and
the final predictive classifiers–support vector machines (SVM) [28], signed distance
function (SDF) [6], and linear discriminant analysis (LDA). Each classifier may be
applied in either linear or kernelized form. We use the Gaussian kernel and adjust
the variance parameter to achieve different levels of non-linear classification (Table
20). In total, we use 30 different classifiers in varying degrees of complexity.
5.2.5 Classification Performance Metrics
There are several method for measuring the performance of a classifier. Each met-
ric examines a different aspect of a classifier. We use three metrics: accuracy, area
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Table 16: Genes validated as differentially expressed between CC and ONC/CHR
renal tumor subtypes from various knowledge sources.
Gene Symbol Knowledge Source Validation Method
CA9 Chen, Clin Cancer Res, 2005 qRT-PCR
CLCNKB Chen, Clin Cancer Res, 2005 qRT-PCR
DEFB1 Schuetz, J Mol Diagn, 2005 qRT-PCR, IHC
LRP2 Schuetz, J Mol Diagn, 2005 qRT-PCR, IHC
PVALB Chen, Clin Cancer Res, 2005 qRT-PCR
STC1 Phan, Pac Symp Biocomput, 2009 qRT-PCR
SLC25A4 Phan, Pac Symp Biocomput, 2009 qRT-PCR
CFTR Phan, Pac Symp Biocomput, 2009 qRT-PCR
PDHA1 Phan, Pac Symp Biocomput, 2009 qRT-PCR
PFKM Phan, Pac Symp Biocomput, 2009 qRT-PCR
NNMT Phan, Pac Symp Biocomput, 2009 qRT-PCR
CP Phan, Pac Symp Biocomput, 2009 qRT-PCR
CFB Phan, Pac Symp Biocomput, 2009 qRT-PCR
COX5A Phan, Pac Symp Biocomput, 2009 qRT-PCR
BAG1 Phan, Pac Symp Biocomput, 2009 qRT-PCR
LY6E Phan, Pac Symp Biocomput, 2009 qRT-PCR
CD99 Phan, Pac Symp Biocomput, 2009 qRT-PCR
AKAP12 Phan, Pac Symp Biocomput, 2009 qRT-PCR
ACAT1 Phan, Pac Symp Biocomput, 2009 qRT-PCR
SPTBN2 Phan, Pac Symp Biocomput, 2009 qRT-PCR
GOT1 Phan, Pac Symp Biocomput, 2009 qRT-PCR
Table 17: Genes validated as differentially expressed between CC and PAP renal
tumor subtypes from an in-house knowledge source.














Table 18: Validated prostate cancer biomarkers identified from literature. These
biomarkers are specific for distinguishing between prostate tumor and normal prostate
tissue.
Gene Symbol Source
SARDH Sreekumar, Nature, 2009
AMACR Luo, Cancer Research, 2002
HPN Sardana, Clin Chem, 2008
MYC Prowatke, British Journal of Cancer, 2007
FASN Prowatke, British Journal of Cancer, 2007
FOLH1 Schlomm, Eur Urol, 2008
Table 19: Validated breast cancer biomarkers identified from literature. These
biomarkers are specific for distinguishing between chemotherapy treatment outcome.
Specifically, for pathologic complete response (pCR) to T/FAC treatment versus resid-
ual disease after a predefined period of time.
Gene Symbol Source
MAPT Rouzier, PNAS, 2005
KI67 Burcombe, Breast Cancer Res, 2006










Table 21: Summary of modeling factors in systematic clinical prediction study.
Modeling Factor Degrees of Freedom Description





Filter: Fold Change, t-test, SAM
Wrapper: SVM, SDF, LDA
Classifiers 30
SVM, SDF, LDA
Linear and Gaussian Kernels
Feature Sizes 6 5,10,15,20,25,30
*We only considered 211 feature selection methods for endpoints D1 and D2
under the ROC curve (AUC), and Matthews Correlation Coefficient (MCC). Accu-
ray and MCC are binary performance metrics, meaning that they do not consider
the confidence, or probability of correct classification–samples are either correctly or
incorrectly classified. AUC, on the other hand, takes into consideration, the degree
of correct or incorrect classifications [8, 76]. Accuracy is highly sensitive to data
prevalence. MCC attempts to correct the sensitivity of accuracy to data prevalence,
but still behaves non-linearly for unbalanced data prevalence. AUC is invariant to
data prevalence, but combines all classification thresholds. Ferri et al. conducted
an extensive examination of several performance metrics [40]. For a more detailed
description of accuracy, MCC, and AUC, refer to Appendix D.
5.2.6 Summary of Systematic Study
In total, we examine several modeling factors for four clinical endpoints, including
swapped training and testing data (Table 21). The primary focus of the study is
on the biological relevance of feature selection methods. However, we also vary the
classifiers and feature sizes. We consider a total of 46,440 predictive models for each
clinical endpoint (with the exception of the breast cancer endpoints, for which we
only consider 37,980 models).
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5.3 Results and Discussion
5.3.1 Data Batch Effect
Each of the four end points differs in terms of clinical focus and difficulty. These
differences in data affect the performance of the resulting predictive models when
tested on external validation data. However, there are other factors that can influence
the reliability of model performance. These factors are primarily related to data
quality and include sample size and batch effect. Both of these factors can bias the
resulting predictive models, especially during the training phase, in which we estimate
the performance of a predictor in order to select model parameters. Among the three
datasets (four clinical endpoints), the renal cancer data from the study by Jones et al.
has the largest batch effect between classes [67] (Figure 34). Furthermore, the batch
effect also translates to a significant difference between the Jones data (endpoint A2
and B2) and the Schuetz renal cancer data (endpoint A1 and B1). We can see in
Figure 34 that there is a distinct separation of clusters between the CC S (Schuetz
Renal Cancer Clear Cell Samples) and CC J (Jones Renal Cancer Clear Cell Samples)
samples as well as between the CC J and CHR J (Jones Renal Cancer Chromophobe
Samples) samples. We expect the batch effect within the Jones data to affect feature
selection and, subsequently, predictive accuracy. For example, the batch effect will
result in selection of a large number of differentially expressed genes purely due to
differences between samples. Consequently, cross validation performance of models
for the Jones data, endpoints A2 and B2, should be optimistic compared to the
validation of these models on the Schuetz data, endpoints A1 and B1. The batch
effect between endpoints A1 and B1 and endpoints A2 and B2 should also decrease
validation performance.
We attempt to correct the batch effect between datasets using quantile normal-
ization [7]. For example, prior to classifying samples in endpoint A2 using predictive
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models created with samples from endpoint A1, we normalize all samples in end-
point A2 using samples from endpoint A1 as the reference distribution. Figure 35,
Figure 36, Figure 37, and Figure 38 illustrate this process. The red lines in-
dicate the distribution of the normalized dataset. Figure 35 and Figure 36 also
confirm the significant batch effect between the Jones data (end points A2 and B2)
and the Schuetz data (end points A1 and B1). In addition to the differences between
lab sources, the differences between these datasets may be attributed to the use of
different probe-level summary normalization methods [62]. Because raw chip data
are available for the Schuetz data, we compute probeset expression values using the
MAS5 algorithm [58]. However, the raw chip data are not available for the Jones
data. Instead we only have access to the probeset expression values computed using
the dChip software package [78]. The batch effect within the prostate and breast
cancer datasets are less prominent due to the availability of raw array data (Figure
37 and Figure 38).
5.3.2 Estimating Performance of Predictive Models
Considering all models for each clinical endpoint, cross validation seems to predict ex-
ternal validation performance very poorly. This is especially true for the renal cancer
data (endpoints A1 and B1) (Figure 39, green and red). Factors that contribute to
poor concordance between cross validation and external validation are likely the small
sample size, the variety of feature selection methods, and data batch effects. Cross
validation is unreliable when the test sample for each fold consists very few samples.
The set of 258 feature selection methods includes many wrapper based methods that
may over-fit when estimating the predictive potential for individual biomarkers. The
cross validation and external validation predictive performance of both the prostate
cancer and breast cancer endpoints (C1 and D1) are more tightly distributed com-








































































Figure 34: Batch effect in the renal cancer microarray data. Data endpoints A1 and
A2 (as well as B1 and B2) are derived from two independent renal cancer studies.
Samples for endpoint A1 were assayed using the HG-Focus Affymetrix chip while
those for endpoints A2 were assayed using the HG-U133A chip. Using hierarchical
clustering, there is a significant batch effect between the two datasets that should be
addressed prior to building any predictive models. The CC J, CHR J, and ONC J
labels identify samples from the A2 endpoint while the CC S, CHR S, and ONC S
labels identify samples from the A1 endpoint. We also see a significant batch effect
within the A1 endpoint between the CC J samples and the group of CHR J and
ONC J samples.
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Figure 35: Batch effect between the A1 and A2 datasets, comparing renal cancer
CC to ONC/CHR. Raw probe level data was not available for the A2 dataset. There-
fore, we used gene expression values produced by different summary normalization
software, resulting in a significant batch effect. Before classifying samples in the A1
dataset using predictive models created from the A2 dataset, we quantile normalize
all samples in the A1 dataset using the A2 dataset as a reference distribution (left).
Likewise, we normalize all samples in the A2 dataset using the A1 dataset as a refer-
ence distribution (right) before classifying samples in A2 using models created from
A1.
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Figure 36: Batch effect between the B1 and B2 datasets, comparing renal cancer
CC to PAP subtypes. Raw probe level data was not available for the B2 dataset.
Therefore, we used gene expression values produced by different summary normal-
ization software, resulting in a significant batch effect. Before classifying samples in
the B1 dataset using predictive models created from the B2 dataset, we quantile nor-
malize all samples in the B1 dataset using the B2 dataset as a reference distribution
(left). Likewise, we normalize all samples in the B2 dataset using the B1 dataset as
a reference distribution (right) before classifying samples in B2 using models created
from B1.
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Figure 37: Batch effect between the C1 and C2 datasets, comparing prostate cancer
tumor tissue to normal adjacent tissue. Compared to the renal cancer datasets, the
batch effect in the prostate cancer datasets is minimal due to the availability of raw
probe level information. All gene expression summarizations were computed using the
same software. Before classifying samples in the C1 dataset using predictive models
created from the C2 dataset, we quantile normalize all samples in the C1 dataset
using the C2 dataset as a reference distribution (left). Likewise, we normalize all
samples in the C2 dataset using the C1 dataset as a reference distribution (right)
before classifying samples in C2 using models created from C1.
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Figure 38: Batch effect between the D1 and D2 datasets, comparing breast cancer
treatment outcomes. Compared to the renal cancer datasets, the batch effect in the
breast cancer datasets is minimal due to the availability of raw probe level informa-
tion. All gene expression summarizations were computed using the same software.
Before classifying samples in the D1 dataset using predictive models created from the
D2 dataset, we quantile normalize all samples in the D1 dataset using the D2 dataset
as a reference distribution (left). Likewise, we normalize all samples in the D2 dataset
using the D1 dataset as a reference distribution (right) before classifying samples in
D2 using models created from D1.
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due to the larger sample sizes and relatively smaller batch effect. Nevertheless, valida-
tion performance is still highly variable, again, due to the variety of feature selection
methods. The predictive performance assessed using the MCC, AUC, and accuracy
all show similar behavior.
Swapping the training and testing data for each clinical endpoint reveals the extent
of the batch effect within the A2 and B2 renal cancer datasets (Figure 40). Recall
that this batch effect results in a large number of highly differentially expressed genes
from feature selection. Here, we see that cross validation is severely optimistically
biased while the variance of estimated model performance remains similar to that of
the original data in Figure 39. The prostate cancer and breast cancer endpoints for
the swapped analysis still have relatively tighter distributions. The prostate cancer
endpoints appear to be less subject to over-fitting in the swapped analysis compared
to the original analysis.
5.3.3 Modeling Factors Affecting Performance
We are interested in identifying modeling factors that most contribute to variance in
prediction performance. For each clinical endpoint, we perform an n-way fixed-effects
analysis of variance (ANOVA). We consider three modeling factors: classifier, feature
size, and feature selection methods. Feature sizes include 5, 10, 15, 20, 25, and 30
(selected as the top N genes after ranking). Feature selection methods include 258
(or 211 for the D1 and D2 endpoints) filter and wrapper-based methods. Classifiers
include 30 linear and kernel based methods. These factors are listed in Table 21.
We isolate performance metrics (MCC and AUC) as well as internal cross validation,
external (blind) validation, and the absolute difference between internal and external
validation.
The type of classifier appears to contribute the largest percentage of variance for
the A1 and A2 endpoints when considering MCC as the performance metric (renal
112






MCC Correlation of Internal Cross Validation to External Validation
All Feature Selection Methods





















(a) Predictive model performance correlation between internal cross validation
and external validation using the MCC metric.
Figure 39: Predictive model performance correlation between internal cross valida-
tion and external validation for the A1, B1, C1, and D1 endpoints. When considering
all models, correlation is generally very poor for the A1 and B1 endpoints (renal can-
cer) due to small sample size as well as batch effect. Validation performance of the C1
endpoint (prostate cancer) is not as variable as the other endpoints. However, cross
validation seems to overestimate predictive performance for this endpoint. Results
are similar for each of the three performance metrics: MCC (39(a)), AUC (39(b),
next page), and Accuracy (39(c), next page).
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AUC Correlation of Internal Cross Validation to External Validation
All Feature Selection Methods





















(b) Predictive model performance correlation between internal cross validation
and external validation using the AUC metric.







Acc. Correlation of Internal Cross Validation to External Validation
All Feature Selection Methods




















(c) Predictive model performance correlation between internal cross validation
and external validation using the accuracy metric.
Figure 39 parts (b) and (c). Figure part (a) and full caption on the previous page.
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All Feature Selection Methods





















(a) Predictive model performance correlation between internal cross validation and
external validation using the MCC metric, swapped training and testing data.
Figure 40: Predictive model performance correlation between internal cross valida-
tion and external validation for the A2, B2, C2, and D2 endpoints. When considering
all models, correlation is generally very poor for the A2 and B2 endpoints (renal can-
cer) due to small sample size as well as batch effect. The batch effect within the A2
and B2 datasets explain the optimistic estimation of cross validation. Results are
similar for each of the three performance metrics: MCC (40(a)), AUC (40(b), next
page), and Accuracy (40(c), next page).
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AUC Correlation of Internal Cross Validation to External Validation
All Feature Selection Methods





















(b) Predictive model performance correlation between internal cross validation
and external validation using the AUC metric, swapped training and testing data.







Acc. Correlation of Internal Cross Validation to External Validation
All Feature Selection Methods




















(c) Predictive model performance correlation between internal cross validation
and external validation using the accuracy metric, swapped training and testing
data.
Figure 40 parts (b) and (c). Figure part (a) and full caption on the previous page.
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cancer, Figure 41). The AUC metric, however, seems to be most affected by feature
size. This result is consistent for internal validation, external validation, and the
absolute difference between internal and external validation. A possible explanation
is that MCC is more sensitive to classifier parameters while AUC is not.
The variance of the MCC metric is also significantly affected by classifier type for
the B1 endpoint (Figure 42, top left). In this case however, the effect of feature size
on AUC prediction performance is not so clear (Figure 42, top right). Feature size
contributes most to the AUC variability of cross validation and external validation
for the B1 endpoint, but is not the predominant contributing factor to the variance
of the difference between CV and EV.
For the prostate cancer data (Figure 43, top right), we see that the feature
selection method is the largest contributing factor to AUC performance variance.
Overall, in all endpoints, MCC variance is most affected by the choice of classifier,
whereas the source of variability in the AUC metric depends on the clinical endpoint.
5.3.4 Biological Knowledge Improves Clinical Prediction Performance
In this section, we isolate the variability due to the feature selection method and de-
termine if any relationship exists between the biological relevance of feature selection
and prediction performance. We begin by removing the majority of feature selection
methods from the population of models for each endpoint and observe any changes
in cross validation and validation performance (Figure 45, Figure 46, Figure 47,
and Figure 48). In Figure 45, we observe immediately that reducing the feature
selection methods to only include the top 10 according to biological relevance removes
a majority of the models that perform poorly for external validation. Endpoints af-
fected most significantly are the renal cancer data, A1 and B1. We also see that
models for the prostate cancer endpoint (C1) reduce to a set that tends to over-fit
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Figure 41: Factors that affect internal cross validation, external validation, and
the difference between internal and external validation for renal cancer endpoints A1
and A2 comparing the CC and ONC/CHR subtypes. The MCC performance metric
seems to be affected by classifier modeling factors, including the kernel and associated
parameters. When using the AUC performance metric, feature size predominantly
affects the variability of performance. The effect of feature selection method, though
small, seems to be larger on the blind validation compared to internal cross validation.
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Figure 42: Factors that affect internal cross validation, external validation, and
the difference between internal and external validation for renal cancer endpoints
B1 and B2 comparing the CC and PAP subtypes. The MCC performance metric
seems to be affected by classifier modeling factors, including the kernel and associated
parameters. When using the AUC performance metric, feature size predominantly
affects the variability of performance. The effect of feature selection method, though
small, seems to be larger on the blind validation compared to internal cross validation.
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Figure 43: Factors that affect internal cross validation, external validation, and the
difference between internal and external validation for prostate cancer endpoints C1
and C2 comparing tumor and normal adjacent tissue. The MCC performance metric
seems to be affected by classifier modeling factors, including the kernel and associated
parameters. When using the AUC performance metric, feature size predominantly
affects the variability of performance. The effect of feature selection method, though
small, seems to be larger on the blind validation compared to internal cross validation.
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Figure 44: Factors that affect internal cross validation, external validation, and the
difference between internal and external validation for breast cancer endpoints D1
and D2 comparing treatment outcomes. The MCC performance metric seems to be
affected by classifier modeling factors, including the kernel and associated parameters.
When using the AUC performance metric, feature size predominantly affects the
variability of performance. The effect of feature selection method, though small,
seems to be larger on the blind validation compared to internal cross validation.
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during cross validation. We may interpret this as an increase in cross-validation per-
formance as biological relevance increases. This is a natural interpretation, since the
biological relevance is measured from the training data. However, this is not the case
for the A1, B1, and D1 datasets, each of which results in only slight increases in cross
validation performance as a whole. The majority of the performance improvements
for A1 and B1 occur in the validation performance. When we further reduce the
space of feature selection methods to only the top method, the distributions of model
performances tightens further (Figure 47 and Figure 48). Of particular note is the
increase in validation performances of A1, B1, and C1 such that the cross validation
performance appears to under-estimate validation performance for the MCC, AUC,
and accuracy metrics (except for endpoint A1 for the accuracy performance metric).
The effect of reducing the feature selection model space is similar after swapping
the training and testing data (Figure 46). Again, due to the batch effect within
the A2 and B2 renal cancer datasets, cross validation tends to over-estimate perfor-
mance. However, we see that reduction of the feature selection methods to the top
10 in terms of biological relevance nominally improves A2 and B2 validation per-
formance and even more so for the top feature selection method (Figure 48). As
we remove feature selection methods, the concordance between the cross validation
estimate and external validation for the prostate and breast cancer endpoints C2 and
D2 improves. In this case, there is no over-estimation of prostate cancer validation
during cross validation. Overall, we see that using more biologically relevant feature
selection methods tends to improve concordance between internal cross validation and
external validation. Additionally, biologically relevant feature selection methods seem
to remove a majority of the poorly performing models in terms of external validation.
A direct examination of external blind validation performance as a function of the
biological relevance of feature selection is more revealing (Figure 49, Figure 50,
Figure 51, and Figure 52). We compute the biological relevance using Equation
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20 with the biological knowledge specifically identified for each clinical endpoint (Ta-
ble 16, Table 17, Table 18, and Table 19). The 46440 (37980 for endpoints D1
and D2) prediction models for each clinical endpoint can be divided into 258 feature
selection methods (211 for endpoints D1 and D2), resulting in 180 models (30 clas-
sifiers x 6 feature sizes). For each feature selection method, we compute the average
external validation performance of the 180 models and plot these as a function of
biological relevance. In all cases, external validation performance is positively cor-
related with biological relevance with statistical significance (p ¡ 0.05). Each of the
clinical endpoints has a varying degree of correlation. Although endpoints A2 and
B2 severely overestimate predictor performance due to an internal batch effect, these
models still show a slight improvement as biological relevance of the feature selection
method increases.
5.4 Conclusion
We have performed a systematic study of the feasibility of predictive biomarkers using
four clinical endpoints. Furthermore, we have shown that using biologically relevant
feature selection methods reduces the variability of predictive performance estimates
and improves overall predictive performance on blind external validation data. The
clinical endpoints in this study are diverse and include renal cancer, prostate cancer,
and breast cancer. Although the incidence of renal cancer is less than that of either
prostate or breast cancer, it is still a significant clinical problem due to the hetero-
geneity of the disease. Renal cancer includes several subtypes that are difficult to
distinguish, yet require different treatment regimens [124]. Thus, clinical biomark-
ers that are able to identify particular subtypes will enable physicians to improve
the success of treatment. In contrast, prostate cancer is the most common form of
cancer in men and early detection usually results in successful treatment. However,
treatment decisions may not be optimal. For example, some patients may require a
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MCC Correlation of Internal Cross Validation to External Validation
Top 10 Feature Selection Methods





















(a) Predictive model performance correlation between internal cross validation
and external validation using the MCC metric, top 10 biologically relevant feature
selection methods.
Figure 45: Predictive model performance correlation between internal cross valida-
tion and external validation for the A1, B1, C1, and D1 endpoints. As the models
are filtered to include only the top 10 biologically relevant feature selection methods,
external validation performance improves. Cross validation of predictive models using
samples from the A1, B1, and D1 datasets generally predict classification performance
on the A2, B2, and D2 data samples, respectively. Cross validation of models created
with C1 data samples tend to over-estimate prediction performance using C2 samples.
Results are similar for each of the three performance metrics: MCC (45(a)), AUC
(45(b), next page), and Accuracy (45(c), next page).
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AUC Correlation of Internal Cross Validation to External Validation
Top 10 Feature Selection Methods





















(b) Predictive model performance correlation between internal cross validation
and external validation using the AUC metric, top 10 biologically relevant feature
selection methods.







Acc. Correlation of Internal Cross Validation to External Validation
Top 10 Feature Selection Methods




















(c) Predictive model performance correlation between internal cross validation and
external validation using the accuracy metric, top 10 biologically relevant feature
selection methods.
Figure 45 parts (b) and (c). Figure part (a) and full caption on the previous page.
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(a) Predictive model performance correlation between internal cross validation and
external validation (swapped) using the MCC metric, top 10 biologically relevant
feature selection methods.
Figure 46: Predictive model performance correlation between internal cross valida-
tion and external validation for the A2, B2, C2, and D2 endpoints. When considering
all models, correlation is generally very poor for the A2 and B2 endpoints due to small
sample size as well as batch effect. The batch effect between classes within the A2 and
B2 endpoints is severe, leading to over-estimation of prediction performance. Despite
this, we see that as the models are filtered to include the top 10 biologically relevant
feature selection methods, external validation performance improves. Cross valida-
tion of predictive models using samples from the C2 and D2 datasets generally predict
classification performance on the C1 and D1 data samples, respectively. Results are
similar for each of the three performance metrics: MCC (46(a)), AUC (46(b), next
page), and Accuracy (46(c), next page).
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(b) Predictive model performance correlation between internal cross validation
and external validation (swapped) using the AUC metric, top 10 biologically rel-
evant feature selection methods.
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(c) Predictive model performance correlation between internal cross validation
and external validation (swapped) using the accuracy metric, top 10 biologically
relevant feature selection methods.
Figure 46 parts (b) and (c). Figure part (a) and full caption on the previous page.
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(a) Predictive model performance correlation between internal cross validation
and external validation using the MCC metric and the most biologically relevant
feature selection method.
Figure 47: Predictive model performance correlation between internal cross valida-
tion and external validation for the A1, B1, C1, and D1 endpoints. As the models
are filtered to include only the most biologically relevant feature selection method,
external validation performance improves even further. Cross validation of predictive
models using samples from the A1, B1, and D1 datasets generally predict classifica-
tion performance on the A2, B2, and D2 data samples, respectively. Cross validation
of models created with C1 data samples tend to over-estimate prediction performance
using C2 samples. Results are similar for each of the three performance metrics: MCC
(47(a)), AUC (47(b), next page), and Accuracy (47(c), next page).
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AUC Correlation of Internal Cross Validation to External Validation
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(b) Predictive model performance correlation between internal cross validation
and external validation using the AUC metric and the most biologically relevant
feature selection method.
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(c) Predictive model performance correlation between internal cross validation and
external validation using the accuracy metric and the most biologically relevant
feature selection method.
Figure 47 parts (b) and (c). Figure part (a) and full caption on the previous page.
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(a) Predictive model performance correlation between internal cross validation
and external validation (swapped) using the MCC metric and the most biologically
relevant feature selection method.
Figure 48: Predictive model performance correlation between internal cross valida-
tion and external validation for the A2, B2, C2, and D2 endpoints. When considering
all models, correlation is generally very poor for the A2 and B2 endpoints due to small
sample size as well as batch effect. The batch effect between classes within the A2
and B2 endpoints is severe, leading to over-estimation of prediction performance. De-
spite this, we see that as the models are filtered to include only the most biologically
relevant feature selection method, external validation performance improves. Cross
validation of predictive models using samples from the C2 and D2 datasets gener-
ally predict classification performance on the C1 and D1 data samples, respectively.
Results are similar for each of the three performance metrics: MCC (48(a)), AUC
(48(b), next page), and Accuracy (48(c), next page).
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AUC Correlation of Internal Cross Validation to External Validation
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(b) Predictive model performance correlation between internal cross validation
and external validation (swapped) using the AUC metric and the most biologically
relevant feature selection method.







Acc. Correlation of Internal Cross Validation to External Validation
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(c) Predictive model performance correlation between internal cross validation and
external validation (swapped) using the accuracy metric and the most biologically
relevant feature selection method.
Figure 48 parts (b) and (c). Figure part (a) and full caption on the previous page.
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End Point A1: Correlation of Biological Relevance























End Point A2: Correlation of Biological Relevance
























End Point A1: Correlation of Biological Relevance
























End Point A2: Correlation of Biological Relevance
























End Point A1: Correlation of Biological Relevance


























End Point A2: Correlation of Biological Relevance



















Figure 49: Biological relevance of feature selection improves predictive model perfor-
mance on blind renal cancer data comparing CC and ONC/CHR subtypes. The cor-
relation between external prediction performance and biological relevance is stronger
when models are trained using the A1 dataset (left column). Although models trained
using the A2 dataset (right column) tend to over-fit, there is still a positive correla-
tion between biological relevance and predictive performance. Correlations are sta-
tistically significant (p < 0.05) for all performance metrics: MCC (top row), AUC
(middle row), and Accuracy (bottom row).
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End Point B1: Correlation of Biological Relevance























End Point B2: Correlation of Biological Relevance
























End Point B1: Correlation of Biological Relevance
























End Point B2: Correlation of Biological Relevance
























End Point B1: Correlation of Biological Relevance


























End Point B2: Correlation of Biological Relevance



















Figure 50: Biological relevance of feature selection improves predictive model perfor-
mance on blind renal cancer data comparing CC and PAP subtypes. The correlation
between external prediction performance and biological relevance is stronger when
models are trained using the B1 dataset (left column). Although models trained
using the B2 dataset (right column) tend to over-fit, there is still a positive cor-
relation between biological relevance and predictive performance. Correlations are
statistically significant (p < 0.05) for all performance metrics: MCC (top row), AUC
(middle row), and Accuracy (bottom row).
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End Point C1: Correlation of Biological Relevance























End Point C2: Correlation of Biological Relevance
























End Point C1: Correlation of Biological Relevance

























End Point C2: Correlation of Biological Relevance
























End Point C1: Correlation of Biological Relevance


























End Point C2: Correlation of Biological Relevance



















Figure 51: Biological relevance of feature selection improves predictive model per-
formance on blind prostate cancer data comparing tumor and adjacent normal tissue.
There is a positive correlation between biological relevance and predictive performance
regardless of the training data, C1 (left column) or C2 (right column). Correlations
are statistically significant (p < 0.05) for all performance metrics: MCC (top row),
AUC (middle row), and Accuracy (bottom row).
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End Point D1: Correlation of Biological Relevance























End Point D2: Correlation of Biological Relevance
























End Point D1: Correlation of Biological Relevance
























End Point D2: Correlation of Biological Relevance
























End Point D1: Correlation of Biological Relevance


























End Point D2: Correlation of Biological Relevance



















Figure 52: Biological relevance of feature selection improves predictive model per-
formance on blind breast cancer data comparing treatment outcomes. There is a
positive correlation between biological relevance and predictive performance regard-
less of the training data, D1 (left column) or D2 (right column). Correlations are
statistically significant (p < 0.05) for all performance metrics: MCC (top row), AUC
(middle row), and Accuracy (bottom row).
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prostatectomy while others may only require radiation treatment. The decision to
use one method or the other may be arbitrary, resulting in sub-optimal treatment.
Many studies have attempted to identify biomarkers that can predict the success of
specific treatment options. Here, we are interested in biomarkers that can distinguish
between prostate cancer tissue and normal tissue adjacent to the cancer tissue. Such
biomarkers may help to improve the accuracy of prostate cancer diagnosis from tissue
biopsies. Breast cancer treatment suffers from similar problems. Due to a wide variety
of treatment options, there are many studies that attempt to identify biomarkers that
predict specific treatment outcomes. Here, we examine predictors that can identify
patients that are likely to respond well to a specific treatment regimen of chemother-
apy [53]. In general, the success of clinical predictors derived from high-throughput
data would greatly improve clinical applications.
The validation performance of our predictors varies widely within each endpoint,
especially for the renal cancer datasets. This variability may be attributed to dataset-
specific factors, such as sample size and batch effect. The renal cancer datasets
were small compared to the prostate and breast cancer data, reflecting the relative
differences in disease incidence. Batch effect within datasets and between training
and testing datasets results in over-fitting, in which the predictive model becomes
specialized to sub-population of patients and cannot generalize to the population as
a whole.
Overall, we have seen that the success of a clinical predictor depends on the feature
selection method. We considered a large variety of feature selection methods, many
of which were found to be biologically irrelevant according to previously validated
biomarkers. Removal of these biologically irrelevant ranking methods improved over-
all validation performance as well as concordance between cross validation estimates
and external validation. Moreover, we found that the biological relevance of a feature






omniBiomarker is a bioinformatics application that serves as both a microarray data
repository as well as a tool for identifying clinically useful candidate biomarkers.
Biomarker identification from high-throughput microarray data for clinical prediction
is sensitive to analysis parameters [88]. As a result, candidate biomarker lists can be
difficult to reproduce, limiting the efficiency of translating candidate biomarker lists
to clinical applications. omniBiomarker addresses this problem by tuning steps in
the analysis pipeline to a clinical problem based on prior biological knowledge [106].
Figure 53 illustrates the data analysis pipeline that omniBiomarker encapsulates
(left panel), with examples of system output (right panel). We can use clinically val-
idated biomarkers as references with which to identify the most biologically relevant
feature selection algorithms. Despite the lag between initial proposal of candidate
biomarkers and final clinical validation, there are still a number of biomarkers that
we can use as knowledge [156]. By integrating knowledge in this manner, we can over-
come the curse of dimensionality problem and increase the reproducibility of clinical
prediction. omniBiomarker also addresses the problem of community accessibility. It
is developed with a focus on not only the novelty of the analysis pipeline, but also
on the integration of these analytical steps into a user-friendly, web-accessible inter-
face. This attribute of bioinformatics tools has become increasingly important as the
gap between clinical applications and bioinformatics narrows. omniBiomarker is also
caBIG-compatible, further increasing the interoperability of its functions with other
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bioinformatics tools in the cancer research community [95].
Not surprisingly, many of these web-based applications implement functionality
for several common steps in the data analysis pipeline. Despite the existence of many
web-based tools for biomarker identification, we are still several steps removed from
clinical applications. Before using these clinical biomarkers in clinical scenarios, we
must interpret and verify their biological validity.
The availability of many software packages for each step in the biomarker iden-
tification pipeline enables us to choose from a variety of methods to suit our needs.
However, the lack of an established data standard impedes our progress when we try
to fit the pieces together [98]. For example, without translating the data format,
we may not be able to use the data output of a quality control and normalization
application in a subsequent clustering or feature selection application. Furthermore,
we sometimes need to translate lists of gene symbols from a feature selection applica-
tion before interpretation with a particular GO application [46]. The goals of these
workflow applications support those of omniBiomarker by speeding up the process by
which bioinformaticians can assess the clinical feasibility of a particular data-specific
workflow. We can extend the philosophy of knowledge-driven algorithm selection to
the more general knowledge-driven workflow selection. Thus, in order confidently
choose a workflow we need to assess many different data analysis paths to determine
the relevance of their results with respect to prior biological and clinical knowledge.
6.2 omniBiomarker: Web-Based Application
The primary aim of the omniBiomarker web-based application is to provide a mi-
croarray storage and analysis engine to the bioinformatics community. The unique
functions of this application include 1) user-specific data privacy, 2) centralized gene
expression data storage and manipulation, 3) a multitude of wrapper-based feature
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Figure 53: The knowledge-guided workflow for identifying differentially expressed
genes consists of several steps (left panel). In step one, we collect high-throughput
-omic data using technology such as microarrays as well as biological knowledge about
the disease of interest. In step two, rather than identifying features using only data-
driven methods, we use biological knowledge to guide the feature selection process
and identify the algorithm that results in rankings with maximal biological rele-
vance. Finally, in step three, we validate the candidate biomarkers with qRT-PCR or
other imaging techniques in order to 1) ensure highly accurate clinical applications
and 2) improve our biological knowledge. We have shown that feature selection is
sensitive to algorithm parameters and that, by selecting algorithms that produce bio-
logically relevant results, we can improve the efficiency of detecting new biomarkers.
The omniBiomarker system, a web-based application which aims to implement the
knowledge-guided workflow, allows users to simultaneously test several algorithms for
feature ranking and selection from high-throughput biological data (right panel).
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parameters, and 5) efficient analysis with a parallelized computing back-end. We de-
signed these functions as modules within a multi-tiered application (Figure 54). The
top-level tier of the application includes the web browser, where all user interactions
take place. Here, users may upload and download gene expression data as well as
gene ranking results. The web interface also provides intuitive controls for manipu-
lating and organizing data and results. All users must login prior to any data access
or manipulation. The second tier of the application includes the logic for displaying
the user interface. In addition, this layer contains simple utility applications for data
normalization and access/retrieval from the database, which is the third tier. The
second web-server tier may also directly access the computation layer, which contains
modules for gene ranking. The computation layer accesses the database layer in order
to retrieve gene expression data and to store analysis results.
omniBiomarker is available for public use. However, access to the system requires
that users register to create a user profile. Once a user has created a profile, he or she
may proceed to upload gene expression data and begin data analysis (Figure 55).
The system accepts gene expression data in either Microsoft Excel or tab-delimited
formats such that each column represents a single microarray sample and each row
represents a gene. The data files may optionally contain information about sample
names or gene names. Gene names are stored in a database under a user-defined
microarray name so that data duplication may not occur for future data uploads
using the same platform. Once logged in, users are presented with an overview of
previously uploaded microarray datasets listed with key pieces of information (Fig-
ure 56). This information includes the user-specified dataset name, a brief dataset
description, the number of samples uploaded, the number of probesets in the mi-
croarray, and the date and time of upload. From here, users may delete datasets, or
































Figure 54: The omniBiomarker web-based application contains four layers. The
client layer contains users’ web browsers and collects input to be relayed to the web
server. The web server layer, in addition to responding to user commands and sending
the appropriate interface commands, contains utilities for uploading and downloading
data to and from the MySQL relational database. The database is the third layer,
accessed by both the web server and computation layers. The computation layer
receives commands directly from the web server layer through a web service.
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Table 22: Normalization functions available in omniBiomarker. Multiple normal-








Log Base e Normalization
Log Base 10 Normalization
Log Base 2 Normalization
Replace Zeros
Replace Zeros and Negatives
Quantile Normalization
(Figure 57). omniBiomarker gives the user flexibility in terms of sample partition-
ing for biomarker identification. After uploading a gene expression dataset, users are
presented with the default sample partitioning according to the labels in the original
data file. However, users may also re-partition datasets by re-labeling samples. For
example, suppose a user uploads a cancer gene expression dataset that contains three
disease subtypes. The user might be interested in identifying biomarkers that are
differentially expressed between subtypes A and B. In this case, the user would need
to create a new data partition, move samples from classes A and B into the new
partition, and re-label the samples (using -1 and 1). The new partition refers to the
original samples and does not duplicate data samples, reducing the overall storage
overhead of the database. omniBiomarker also includes a function to automatically
create stratified n-fold cross validation partitions of datasets in order to compute an
estimate of predictive performance.
From the data management interface, users may also apply normalization pro-
cedures to the data (Table 22). The normalization procedures include common
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Figure 55: omniBiomarker interfaces for login access and data upload. Users must
register before accessing the system through the login screen (top). After logging in,
users are presented with a list of datasets that they have previously uploaded. New
users will not see any datasets. Users can upload data using a web-form (bottom).
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Figure 56: omniBiomarker data list interface. The dataset list displays standard
information about the particular dataset, including data name, a brief description,
number of samples, number of probesets in each microarray sample, the microarray
type, and the upload date. From this screen users may select a particular dataset for
further analysis or delete the dataset by clicking the red ‘X’ icon.
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Figure 57: omniBiomarker interface for data and sample management. From this
data management interface, users may re-partition microarray samples into differ-
ent groups prior to feature selection analysis. Additionally, users may apply pre-
processing normalization steps to the data, download the normalized data, and initi-
ate feature selection analysis on the normalized data. This interface also includes a
function to automatically partition the data for stratified n-fold cross validation.
transformations such as column and row mean centering, median centering, or z-
score (mean centering and division by the standard deviation). omniBiomarker also
includes simple procedures such as log transforms and replacement of missing val-
ues as well as more sophisticated methods such as quantile normalization. Quantile
normalization forces all samples in the dataset into a common mean distribution [7].
Multiple normalization procedures may be applied sequentially to each dataset in a
single step.
From the data management interface, users may select a dataset–or a normal-
ized version of a dataset–and proceed to the feature ranking analysis interface. om-
niBiomarker provides primarily wrapper-based feature ranking methods. Wrapper-
based methods rank features by computing an estimate of classification performance
via a cross validation or bootstrapping procedure [10, 151]. This procedure is gener-
ally more computationally intensive compared to filter methods such as fold change
or SAM [141]. However, wrapper-based methods are desirable when the end goal is to
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construct a clinical predictor, as the features are selected based on estimated predic-
tion performance. Wrapper-based methods are highly parametric. They vary in terms
of classification method as well as error estimation method. Furthermore, each classi-
fier is subject to its own parameters–including kernels and associated parameters–that
need to be tuned. Although cross validation and bootstrap error estimation methods
are well known as unbiased estimators, some studies have shown that these methods
may not perform as expected in small-sample conditions [10, 44]. Thus, we provide
a variety of error estimation methods, including the extremely biased, but very effi-
cient resubstitution method. Figure 58 is a screenshot of the omniBiomarker feature
ranking analysis interface. In addition to classifier and error estimator options, om-
niBiomarker provides parameters to tune computational efficiency. omniBiomarker
allows us to rank a gene expression dataset using multiple parameters simultaneously.
For example, submitting N parameter combinations into the ranking system will rank
the dataset N times. After processing, users may download and examine all N rank-
ings to identify the most biologically relevant. Multi-parameter ranking analysis is
very computationally intense. As such, omniBiomarker partitions the ranking pro-
cedures across multiple compute nodes based on the data distribution parameters.
All analysis parameters for omniBiomarker are listed in Table 23. After selecting
analysis parameters and submitting the job, the user may control the job from the
analysis results and queuing interface (Figure 59). As the ranking proceeds, the
user can observe the job status and download results once analysis has completed.
The downloaded results are formatted such that users can correlate ranking analysis
parameters with ranking results, facilitating parameter tuning based on the quality
of results.
All omniBiomarker data are stored in a relational database that organizes infor-
mation about expression values as well as analysis results (Figure 60). Microarray
samples are stored in a multi-level hierarchy in order to the maximize flexibility of
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Figure 58: omniBiomarker gene ranking analysis form. This interface provides the
user with several wrapper-based ranking methods that include three classifiers, four
classifier kernels, and several error estimation methods. In addition, users may also
tune the distributed computing parameters.
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Table 23: Analysis options in the omniBiomarker web-based application.
omniBiomarker Analysis Options
Classifier Description/Parameters
Support Vector Machine (SVM) SVM cost, EPS (machine precision)
Linear/Fishers Discriminant (FD) Regularization Factor (gamma)
Signed Distance Function (SDF) Regularization Factor (gamma)
Classifier Kernel Description/Parameters
Linear N/A
Polynomial Coefficient, Degree, Gamma
Radial Basis Gamma
Sigmoid Coefficient, Gamma
Error Estimation Method Description/Parameters
Resubstitution N/A
Cross Validation # of Iterations, # of Folds
Bootstrap # of Iterations, Regular/0.632/0.632+
Additional Description/Parameters
# of Processors # of processors to distribute job
Replicate Chunks # of genes/rows distributed to each CPU
Parameter Chunks # of parameters distributed to each CPU
Figure 59: omniBiomarker interface for analysis results and job queue. This in-
terface reports the status of all submitted feature ranking jobs. Once analysis has
completed for a job, users may download the results in either Microsoft Excel or
tab-delimited text format.
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data analysis while reducing overall storage requirements. A dataset typically con-
sists of several microarray samples partitioned into specific phenotypic classes. These
partitions are called ‘label sets’ and serve to reduce data duplication. Each dataset
is associated with metadata tables so that each biomarker can be directly linked to
the appropriate annotation information. In addition to sample storage tables, the
database also includes several tables to store biomarker rankings, analysis parame-
ters, and knowledge about biomarker validation results.
Information about the dataset platform (type of microarray chip, etc.) is stored in
a separate metadata table. Datasets can be normalized or pre-processed in a variety
of ways. The normalized data is stored in a separate table. There is always at least
one normalized dataset for each dataset. The default normalized data is called the
‘original’ data. If we want to normalize the original data by, for example, scaling all
expression values, we would create a new normalization record. As a result, we would
then have two normalized versions for the dataset: the original and the normalized.
Each normalized dataset is linked to multiple items in the ‘orig sample’ table.
Each record in the ‘orig sample’ table is a unique microarray sample, containing up
to thousands of gene expression values. We want to be able to partition the samples
into different classes without duplicating data. The following is an example of a data
re-partitioning scenario:
Suppose that a microarray dataset has several samples: (1 2 3 4 5 6 7 8 9).
If samples (1 2 3 4) are microarray samples from patients that exhibit a specific
symptom and samples (5 6 7 8 9) are from patients that have no symptoms, then we
want to compare the two groups (1 2 3 4) and (5 6 7 8 9) to identify biomarkers that
are differentially expressed between these groups. Then, according to the relational
database diagram, the ‘data set’ entry will be linked to one ‘label set’ entry that will
be named ‘partition1’, for example. The ‘partition1’ ‘label set’ will be linked to two
items in the class table: ‘class1’ for (1 2 3 4) and ‘class2’ for (5 6 7 8 9). Each
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of these class records will be linked to 4 and 5 unique records in the sample table,
respectively. Finally, each record in the sample table will be linked to a single record
in the ‘orig sample’ table. The ‘orig sample’ record is what contains the actual data
for the microarray sample.
Now suppose that physicians discovered another symptom to distinguish these
patients and the symptom is present in patients (1 2 3 4 5 6) but not in patients
(7 8 9). We are also interested in identifying differentially expressed genes between
these two groups. In this scenario, we define another record in the ‘label set’ table
called ‘partition2’ that is linked to two more items in the class table called ‘class1’
and ‘class2’. Although these class names are the same as the previous partitioning,
the ‘class id’ and ‘label set id’ values will be different. These class records will be
associated with another unique set of records in the sample table, but these samples
point back to the same items in the ‘orig sample’ table as the ‘partition1’ ‘label set’.
Using this data scheme, omniBiomarker can efficiently store gene expression data
with minimal data duplication.
6.3 omniBiomarker: caBIG Grid Services
Web-based omniBiomarker is usable as a standalone application. Users may upload
data in a simple format and retrieve results in a similar format. However, as with
many other bioinformatics applications, these data formats may not be compatible
with other similar applications. Because omniBiomarker primarily provides feature
selection functionality, it would be natural to expect users to use omniBiomarker in
conjunction with other applications. For example, prior to feature selection, users
may need to assess the quality of their microarray data with an application such as
caCorrect [137]. The data format that caCorrect produces is similar, but not com-
patible with the data format required by omniBiomarker. Similarly, omniBiomarker














































































































































Figure 60: omniBiomarker web-based application relational database. This
database is designed to store microarray data as well as feature selection results.
Microarray data are stored in a hierarchy that allows users to normalize data and
assign samples into classes for supervised analysis. The ‘analysis’ table stores all
parameters for a particular feature ranking job as well as the ranking results (linked
with the ‘score’ table) so that users may assess the results from multiple ranking
analyses and select the most biologically relevant result.
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list of rank scores. Users can manually filter this data to extract the top genes for
further interpretation with an application such as GOMiner [154]. Of course, the
developers of omniBiomarker can simply change the data input and output require-
ments. However, there are many existing bioinformatics applications and developers
may not feel the need to alter their applications. Furthermore, users may not want
to use caCorrect or GOMiner. They may want to use dChip or GOStat for their
microarray quality control and gene function interpretation needs, which may very
well require completely different data formats [78, 4]. As such, we see a significant
lack of interoperability among bioinformatics applications.
Recently, the National Cancer Institute (NCI) has initiated the Cancer Bioinfor-
matics Grid (caBIG) project, which attempts to tackle the problem of interoperabil-
ity between bioinformatics applications. Specifically, they focus on bioinformatics
research in the area of oncology and developed a semantically interoperable infras-
tructure for bioinformatics applications [95, 87]. The primary function of caBIG is
to define a set of standards and control a centralized vocabulary for potential caBIG-
compatible applications. This standardization forces software applications to reuse
data structures and vocabulary, increasing overall interoperability [74, 99]. Each
application that intends to become caBIG-certified must be subject to a rigorous
review process in which every data element that is part of the application’s input
or output routines is mapped to a predefined semantic vocabulary term [26, 42].
caBIG is a significant undertaking because of the existence of many bioinformatics
applications–many of which will not become certified–as well as the difficult task of
defining controlled vocabulary terms for each bioinformatic data element. Indeed,
the lack of software interoperability is not constrained to only the bioinformatics re-
search community. The ramifications of a fully interoperable infrastructure may also
improve health care informatics in general [73].
We have begun the process of certifying components of omniBiomarker as caBIG
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compatible. caBIG requires that the primary and publicly available data analysis
routines of a bioinformatics application be exposed as a web service. Web services
are well-defined application programming interfaces (API) that can be accessed by
any application that knows the required input parameters and expected output. The
omniBiomarker web-based application contains many functions for data storage, pre-
processing, and feature selection. However, we only translate basic feature ranking
functions into the caBIG standard due to the availability of other caBIG-certified
applications that serve as data repositories such as caArray. Therefore, the caBIG-
certified omniBiomarker application no longer stores microarray data. Rather, it
retrieves all data for analysis from caArray. We implement two basic functions for
feature ranking: rankGenes() and getGeneRanks() (Table 24). The input parameter
for the rankGenes() function specifies the dataset, classifier, and error estimation
method for feature ranking. This function returns a reference object, which may be
passed to the getGeneRanks() function to retrieve the list of ranking results once
analysis is complete.
The overall structure of the caBIG omniBiomarker system is relatively simple
compared to the original web-based application (Figure 61). Since only one set
of ranking parameters may be executed at once, the compute cluster is no longer
required, reducing the number of system layers to three. The web services can be
invoked by any software client that understands the web service interfaces. Typically,
the client application is a Java-based and also provides an interface for user interac-
tion. The application layer includes caGrid system functions as well as the C/C++
application that performs the actual gene ranking. Gene ranking analysis parameters
and results are stored in a simplified relational database that only contains a single
table. Results are stored indefinitely and may be retrieved as long as the analysis ID
is known.
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Table 24: caBIG service interfaces for omniBiomarker.

























Figure 61: omniBiomarker caBIG System. In addition to semantic standardization,
conversion of omniBiomarker to a caBIG-enabled set of grid services simplifies the
overall system architecture. Client applications access the services through two caBIG
web services, rankGenes() and getGeneRanks(). These web services initiate a gene
ranking analysis and retrieve the ranking results, respectively. Ranking results are
still stored in a simplified MySQL relational database. However, all microarray data
are stored in the standardized caArray server.
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The caBIG review process for certification requires that developers create well-
defined object models (UML diagrams) for each data class that is passed to and
from their service functions. The omniBiomarker rankGenes() function requires the
GeneRankParameters class as input (Figure 62). This class contains several other
classes that specify the classification and error estimation method used for wrapper-
based feature ranking. Additionally, the getGeneRanks() function returns the Gen-
eRankResults class, which contains information about analysis parameters as well as
the ranking results (Figure 63).
caBIG also requires that each data element within the UML diagram have well-
defined vocabularies [26]. These vocabulary terms are centrally stored and managed
by caBIG such that future applications may share the same terms, resulting in an
overall increase in application interoperability. We defined terms for omniBiomarker
that pertain to wrapper-based feature ranking methods (Table 25). Because om-
niBiomarker is one of the first analytical applications in caBIG, these terms were
defined specifically for omniBiomarker, but may now be used by other applications.
6.4 Conclusion
omniBiomarker is a web-based bioinformatics application that serves as both a mi-
croarray data repository as well as a tool for identifying clinically useful candidate
biomarkers. The theoretical foundation of omniBiomarker addresses the ill-posed
problem of biomarker identification by tuning steps in the analysis pipeline using
prior biological knowledge. It is essential that all the analytical steps in the biomarker
identification process be recorded in order to later identify the parameters that are
most likely to result in biologically relevant solutions. The omniBiomarker system
provides users with a data storage and interpretation interface that enables easy
tracking and visualization of feature ranking results. Furthermore, the application
recognizes the need for high-performance computing in order to allow users to assess
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a large population of feature ranking algorithms simultaneously and efficiently.
omniBiomarker also addresses the problem of community accessibility. It is de-
veloped with a focus on not only the novelty of the analysis pipeline, but also on
the integration of these analytical steps into a user-friendly, web-accessible inter-
face. This attribute of bioinformatics tools has become increasingly important as the
gap between clinical applications and bioinformatics narrows. omniBiomarker is also
caBIG-compatible, further increasing the interoperability of its functions with other






- gaussianVariance:  Double
- kernelType:  String
- polynomialCoefficient:  Double
- polynomialExponent:  Integer
- SVMCost:  Double
- type:  String
edu.gatech.bme.omnibiomarker::
ErrorEstimatorMethod
- bootstrapIterations:  Integer
- bootstrapType:  Integer
- crossValidationGroups:  Integer
- crossValidationIterations:  Integer
- type:  String
gov.nih.nci.caarray.domain.project::Experiment
- assayType:  String
- date:  Date
- description:  String
- designDescription:  String
- publicIdentifier:  String
- publicReleaseDate:  Date
- qualityControlDescription:  String
- replicateDescription:  String
- title:  String
+ getHybridizations() : List<Hybridization>
org.apache.axis2.addressing::
EndpointReference
- address:  String
+ getAddress() : String

















Figure 62: omniBiomarker UML diagram for the GeneRankParameters class. This











- score:  Double
gov.nih.nci.caarray.domain.array::Gene
- ensemblgeneID:  String
- entrezgeneID:  String
- fullName:  String
- genbankAccession:  String
- genbankAccessionVersion:  String
- symbol:  String













Figure 63: omniBiomarker UML diagram for the GeneRankResults class. This
class is returned from the getGeneRanks() function and includes information about
the analysis parameters as well as the analysis results.
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C78534 A family of continuous probability dis-




C78538 A mathematical expression formed by




C78542 A classification method that will con-
struct a hyperplane between two sets
of data such that it maximizes the
margin between the hyperplane and
the nearest samples.
Kernel Function C78544 A function that measures the dis-
tance between two expression vectors
as the data are projected into higher-
dimensional space.
Cross Validation C78545 A statistical method of partitioning a
sample of data into subsets such that
the analysis is initially performed on a
single subset, while the other subsets
are retained for subsequent use in con-




C78547 A method for estimating properties of
a dataset by measuring those proper-
ties when sampling from an approxi-
mating distribution.
Cost Function C78559 A function or expression that is either
maximized or minimized in order to
obtain the optimal solution for a math-
ematical problem.
Optimization C78561 A process that attempts to find the




Biomarkers are essential for the successful treatment of cancer since they enable early
detection of the disease before significant symptoms arise [156]. Moreover, patholo-
gists may use biomarkers to acquire information from tissue biopsies that may not
be readily apparent using traditional examination techniques. A cancer detection
screening using biomarkers is essentially a clinical predictor that assigns patients to
categories of disease presence/absence or degree of disease severity. Accurate as-
signment of patients into these categories would optimize therapeutic decisions and
improve treatment success rates.
Before we can use biomarkers in the clinic, however, we must subject them to a
rigorous validation process. This process of biomarker discovery and clinical applica-
tion is commonly referred to as translational research [112]. Indeed, there are many
existing candidate biomarkers due to the advent of high-throughput assay platforms
such as gene expression microarrays. Correspondingly, we have seen a sharp increase
in bioinformatics applications and algorithms designed to process the resulting data
from high-throughput technology. However, without proper validation, many of these
candidate biomarkers may never be used in a clinical setting. Thus, the number of
candidate biomarkers is vastly greater than the number of biomarkers actually applied
to patients. Validation of a biomarker is a confirmation of accuracy, reproducibility,
and effectiveness in detecting disease [156]. Gene expression microarrays, the pre-
dominant method for detecting candidate biomarkers, suffer from low specificity of
detections due to the high-dimensionality of the data. Validation technologies such
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as qRT-PCR, protein microarrays, and tissue microarrays are generally sensitive, re-
producible, and accurate. After laboratory validation, however, these biomarkers are
still subject to rigorous clinical testing prior to final application.
When applying the multitude of existing bioinformatics algorithms to a highly
variable population of clinical data, we must consider two well-known machine learn-
ing theories: the ‘No Free Lunch’ and the ‘Ugly Duckling’ theorems. The ‘No Free
Lunch’ theorem states that there is no single machine learning algorithm that per-
forms well for all datasets [32]. In the domain of clinical prediction, this theorem
implies that a particular set of classification parameters and feature selection meth-
ods may be appropriate for a specific clinical dataset, but not for others. The related
‘Ugly Duckling’ theorem applied to bioinformatics states that domain-specific knowl-
edge plays an important role in identifying informative feature sets. Thus, there is
no problem-independent feature selection method that can be generally applied to all
problem domains successfully [32]. The heterogeneity of clinical data and the avail-
ability of many bioinformatics algorithms for feature selection and classification pose
a difficult problem. Feature selection and clinical prediction will generally lack repro-
ducibility when applying similar procedures to different datasets, even if the datasets
are clinically similar.
Fortunately, the availability of validated biomarkers adds an extra dimension to
bioinformatics algorithms. Rather than only relying on high-throughput data that
may suffer from technical as well as biological variability, we may use these validated
biomarkers as domain knowledge to guide steps in the analytical pipeline. During
the feature selection process, biological knowledge can narrow the space of relevant
feature selection algorithms and improve the efficiency of detecting novel biomarkers
that are likely to validate [106]. Furthermore, feature selection is an essential step in
building clinical predictors. The results presented in Chapter 5 indicate that the
reproducibility and accuracy of clinical predictors improves when we narrow the space
161
of relevant feature selection methods using prior knowledge.
Finally, the reproducibility of bioinformatics results suffers from a lack of inter-
operability between various bioinformatics software applications. We have designed
an application, called omniBiomarker, to facilitate the guidance of biomarker iden-
tification and, eventually, clinical predictor assessment. This application improves
reproducibility by tracking all analytical steps so that users may visualize and iden-
tify optimal problem-specific parameters. Moreover, omniBiomarker is also designed
to be compatible with the NCI Cancer Bioinformatics Grid (caBIG) in order to ensure
that the application is semantically interoperable with other bioinformatics applica-
tions. caBIG compatibility also ensures that omniBiomarker is accessible to a wide
community of scientists that are interested in knowledge-guided biomarker identifica-
tion and clinical prediction.
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APPENDIX A
MODELING KNOWLEDGE IN BIOMARKER
IDENTIFICATION
In Chapter 4, we defined gene expression datasets using the variables ~xin and yn
that represent an observation n for feature set i and a class label. These variables are
single observations from the random variables ~X i ∈ Rp and Y ∈ {0, 1}. Recall that
p represents the number of genes in each gene set and is much smaller than `, which
is the total number of genes in a dataset (p < `). ~X i and Y are jointly distributed.




2), . . . , (yN , ~x
i
N)) as a vector of all samples from a
gene set i. ~di is a single observation from the random variable ~D.
The function αi = hθ(~di) assigns to each gene set a score that represents the
differential expression of that gene. αi is a single observation of the random variable
A. The variable θ ∈ Θ = {θ1, θ2, . . . , θϑ} is a meta-parameter that characterizes the
ranking function. Gene set ranking results are highly sensitive to θ. Thus, we want to
identify the θ that produces the most biologically relevant ranking according to prior
knowledge specific to the dataset. We can define prior knowledge for each gene set
using the variable ri, an observation of the random variable R ∈ {0, 1}. ri represents
the biological relevance of the gene set i to the ranking problem. Generally, we want
gene sets with ri = 1 to be ranked more favorably than gene sets with ri = 0. The
random variables ~D and R are jointly distributed.
Since ~D and R are jointly distributed and the distribution of A is dependent on
both ~D and the ranking method, θ, then A, R, and θ are also jointly distributed.
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Thus, we can define conditional density functions for A as
f0,θ(α) = f(α|θ, R = 0) (21)
f1,θ(α) = f(α|θ, R = 1)
f0,θ(α) represents the distribution of rank scores for all biologically irrelevant gene
sets and some ranking metric, θ. Likewise, f1,θ(α) represents the distribution of rank
scores for all biologically relevant gene sets. In the following sections, we derive
methods for examining these distributions in order to choose the most biologically
relevant ranking metric, θ. We can use maximum likelihood or maximum a posteriori
methods to choose θ.
The choice of ranking method, θ, affects the distributions of f0,θ(α) and f1,θ(α).
Assuming that lower α indicates a more differentially expressed gene set, the most
biologically relevant θ should correspond to distributions of f0,θ(α) and f1,θ(α) that
are maximally separated with the expectation of f1,θ(α) less than that of f0,θ(α). The
biological relevance of θ is equal to the probability that observations from the f1,θ(α)












which is equivalent to the area under an ROC curve (AUC). For example, if we define









represent the false positive rate (FPR) and true positive rate (TPR) of identifying
relevant gene sets. All gene sets with α < τ are classified as relevant. x(τ, θ) and






y(τ, θ)x′(τ, θ)dτ, (24)
which is equivalent to Equation 22.
In practice, we do not know the distribution of f1,θ(α) since our knowledge of the
biologically relevant genes in a dataset is limited. In fact, our knowledge set consists
of the set of k gene sets, Gk = {g1, g2, . . . , gk}, where k  m and m is the total
number of gene sets. Using this knowledge, we can simplify the biological relevance










We can further estimate the f0,θ(α) distribution directly from the gene sets that are













where I(x) is the indicator function that evaluates to one when x is true and zero
otherwise. This is a direct empirical estimate of the probability that observations
from the f1,θ(α) distribution are less than observations from the f0,θ(α) distribution:





where i ∈ Gk and j /∈ Gk.
A.1 Maximum Likelihood (ML) Estimation of the Optimal
Ranking Metric
We want to choose a θ that maximizes the biological relevance of ranking with respect
to a given set of knowledge. Normalizing Equation 26 results in a probability mass












where mCj is the total number of combinations containing j elements out of m total
elements and Sij is a gene set that contains the i
th combination of j elements. We can
now define the likelihood function as
L(θ) = P (Gk|θ) (29)







The denominator of Equation 28 is invariant to θ because it is summed over all gene




A.2 Maximum A Posteriori (MAP) Estimation of the Op-
timal Ranking Metric
We can also identify the most biologically relevant ranking metric, θ, using the max-
imum a posteriori method. If we know from previous experiments that some feature
selection methods tend to perform better than others for particular datasets, we can









If we are given additional information about n biologically relevant genes, G′n, then






















CLASSIFICATION METHODS FOR GENE RANKING
AND CLINICAL PREDICTION
B.1 Support Vector Machines (SVM)
The support vector machine (SVM) classifier computes a hyperplane that separates
groups of samples with maximal margin. In other words, the algorithm optimally
places the hyperplane such that its distance to the nearest samples is maximized. A
detailed description of the SVM can be found in the book by Cristianini et al. [28].
In this work, we use an implementation of the SVM by Lin et al. [20].
B.2 Signed Distance Function (SDF)
The signed distance function (SDF) classifier is comparable to the SVM classifier in
terms of performance [6]. The classifier fits a linear discriminator to signed distances
assigned to each sample in the training set. We can estimate signed distances in a
number of ways such that the sign of the distance indicates class label. A simple
method for estimating distances computes the smallest distance from a sample to
another sample of opposite class. We can then assign each sample xi a signed distance
di equal to half of the smallest distance times the class label (+/ − 1). The original
authors of the SDF technical report suggested using least squares to solve the linear
relation
y = w · x + b (35)
where each equation to be solved is
di = w · xi + b (36)
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with i = 1 . . . n training samples, w and xi are m dimensional vectors, and m is the
number of features. After solving for w and b, we can predict the label for a future
test sample, x, with
l(x) = w · x + b. (37)






where k() can be any of a number of kernels (kernel reference). We can solve the
kernelized problem by solving the following system of equations for the vector α.
(K + nγI)α = d, (39)
where γ is a regularization factor to ensure that the matrix is positive definite, I is the
identity matrix, α is a vector of weights, and d is a vector of the n signed distances.
γ can usually be assigned a very small value, 0.001.
Once we have solved for the vector α, the signed distance of a future test sample






after which we may determine the class assignment by examining the sign of the
distance, g(x).
B.3 Linear Discriminant Analysis (LDA)









NC(µC − x̄)(µC − x̄)
T (42)
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(xi − µC)(xi − µC)
T . (43)
µC is the mean of samples within class C, NC is the number of samples in class C,
and x̄ is the mean of samples in all classes. We can simplify the maximization of the
objective to the following eigenvalue problem
SBw = λSW w (44)
from which the linear discriminant hyperplane is the leading eigenvector of the matrix
S−1W SB. This solution gives us the hyperplane orientation but not the threshold. We
can compute the classifier threshold by assuming that the optimal hyperplane passes
through a point directly between the two class means. Thus, the final discriminant
function is
l(x) = w · x + b (45)
where




(µ1 + µ2) (47)
and µ1 and µ2 are the means of the samples in each class.
The LDA classifier can also be kernelized to handle non-linear problems. We
can map samples, x, to a different feature space using a function Φ(x) and a kernel
function:
k(xi, xj) = Φ(xi) · Φ(xj) (48)
We do not need to explicitly evaluate Φx as long as we know the kernel function–e.g.,
linear, polynomial, radial basis (Gaussian), or sigmoid. In the feature space, we can



























`). n is the
total number of samples, ni is the number of samples in class i, j = 1 . . . n, and x
i
`
is the `th sample of class i. Km is an n by nm matrix composed of the elements
(Km)ij = k(xi, x
m
j ) where i = 1 . . . n and j1 . . . nj. The optimization problem using





The solution to this optimization problem is the vector α which corresponds to the






The resulting classification function is
g(x) = wΦ · Φ(x) + bΦ. (53)
It is not a problem that Φx is not known explicitly, since





bΦ is the threshold in the kernelized feature space
bΦ = −wΦ · mΦ (55)




























































i is the i
th sample of class 1 (or 2). The final kernelized LDA classifier is







FDA MICROARRAY QUALITY CONTROL PHASE II
(MAQC-II) PROJECT
The FDA recently conducted a large-scale study on the feasibility of using microar-
ray data for clinical prediction. In a collaboration of 36 data analysis teams (DAT),
the Microarray Quality Control Consortium (MAQC) analyzed six large microarray
datasets that covered 13 clinical and toxicity endpoints. Each DAT was free to con-
struct a data analysis protocol (DAP) within certain guidelines. These guidelines
required that all predictive models be assessed using full cross validation (10 itera-
tions of 5-fold cross validation) and that each DAT select a single candidate model for
testing with a blind validation dataset. In general, the prediction models submitted
by the teams were diverse, resulting in a wide variety of prediction performances.
Overall correlation of internal cross validation and external validation scores was rea-
sonable. However, within each endpoint and for each DAT, concordance of internal
cross validation and external validation was variable. DATs were also required to
swap the training and testing data to determine if the performance of their predictors
could be replicated when sample populations change.
Figure 64 and Figure 65 are detailed summaries of the correlation of internal
and external validation for each DAT and endpoint for both the blind (Figure 64) and
swapped (Figure 65) experiments. Summarizing the positive (green) and negative
(red) correlations reveals that AUC performs better than MCC and accuracy in terms
of fraction of positive correlations (Figure 64(d) and Figure 65(d)).
Although correlations are computed using only models within each DAT and end
point pair, we must still consider the diversity of models within in each subgroup.
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A DAT with a diverse set of models may artificially inflate the correlation if, for
example, the range of performance scores is large. As such, we compute the relative
diversity of each DAT (blue horizontal bars on the right side of Figure 64(b) and
Figure 65(b)). The diversity is the number of unique feature selection and classifier
pairs within the total set of models for each DAT. Examining Figure 64(b) closely,
we see that DAT24 and DAT22 have the highest model diversity. However, this does
not lead to predominately positive correlations. Similarly, DAT29 and DAT20 have a
relatively less diverse set of models, yet produced more positive correlations. We also
examine the absolute covariance of cross validation and external validation, since the
variance of performance scores may also inflate the correlation coefficient. Absolute
covariance for each DAT and end point pair is represented as a small black bar, the
length of which is proportional to absolute covariance. Generally, a large absolute
variance corresponds to a significantly positive correlation. However, some cases, such
as for DATs in endpoint A, are negatively correlated or are not significantly correlated
but still have a high absolute covariance. Thus, a large range of performance metric
scores may usually lead to a positive correlation, but not in all cases. Figure 64(c)
and Figure 65(c) are summaries of positive and negative correlation for each end
point, ordered by decreasing positive minus negative correlation. Endpoints M and
I, both of which are the result of random class label assignment, have the worst
performance in terms of correlating cross validation and external validation. The
order of the end points roughly follows the order of increasing prediction difficulty.
Data analysis teams in the MAQC consortium selected candidate models using
different classification performance metrics. In Figure 66, we investigate the effect
of the performance metric on candidate model selection using cross validation results
from 36 data analysis teams and 13 data endpoints. Intuitively, one would assume
that that a classification model that performs well according to some metric ‘A’ should
also perform well according to some other metric ‘B’. However, according to Figure
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Original Training and Validation Data
MCC Accuracy AUC
(b) Correlation between predictive model internal cross validation and external blind validation.
Figure 64: Correlation of predictive model internal cross validation performance to
external blind validation performance. 64(b): DATs computed classification model
performance using three performance metrics (MCC, accuracy, and AUC) averaged
over 10 iterations of 5-fold cross validation. At least three models from both internal
cross validation and external validation are required to compute correlation for each
DAT and end point pair. Light gray squares indicate that only zero, one, or two mod-
els are available. DATs that have not provided enough data to compute correlation
for any end point have been excluded. Green squares indicate a positive correlation
between internal cross validation scores and external validation scores. Red squares
indicate negative correlation. The brightness of red and green squares indicates the
degree of correlation, i.e., a larger absolute Pearson’s correlation coefficient results in
a lighter square. Dark gray squares indicate that the p-value of correlation is larger
than 0.1. The black bar within each box represents the absolute covariance. Data
analysis teams are sorted from top to bottom by decreasing number of endpoints
analyzed, then by decreasing total number of models. Endpoints are sorted from left
to right by increasing percentage of positive correlations minus negative correlations.
The image bar on the right summarizes each DAT with the percentage of positive
correlations (green), negative correlations (red), and relative diversity of the DAT
(blue). Diversity is a measure of the number of unique feature selection/classification
methods used. 64(c) (next page): Summary of the positive and negative correla-
tions for each end point. 64(d) (next page): Summary of the positive and negative
correlations for each performance metric.
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(d) Summary of Performance Metrics: Correlation of internal cross validation to external blind vali-
dation.
Figure 64 parts (c) and (d). Figure parts (a) and (b) and full caption on the previous
page.
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Swapped Training and Validation Data
MCC Accuracy AUC
(b) Correlation between predictive model internal cross validation and external validation after swap-
ping the training and testing data.
Figure 65: Correlation of predictive model internal cross validation performance
to external validation performance after swapping training and testing data. 65(b):
DATs computed classification model performance using three performance metrics
(MCC, accuracy, and AUC) averaged over 10 iterations of 5-fold cross validation.
At least three models from both internal cross validation and external validation are
required to compute correlation for each DAT and end point pair. Light gray squares
indicate that only zero, one, or two models are available. DATs that have not pro-
vided enough data to compute correlation for any end point have been excluded.
Green squares indicate a positive correlation between internal cross validation scores
and external validation scores. Red squares indicate negative correlation. The bright-
ness of red and green squares indicates the degree of correlation, i.e., a larger absolute
Pearson’s correlation coefficient results in a lighter square. Dark gray squares indi-
cate that the p-value of correlation is larger than 0.1. The black bar within each
box represents the absolute covariance. Data analysis teams are sorted from top to
bottom by decreasing number of endpoints analyzed, then by decreasing total number
of models. Endpoints are sorted from left to right by increasing percentage of posi-
tive correlations minus negative correlations (using the original, not swapped, data).
The image bar on the right summarizes each DAT with the percentage of positive
correlations (green), negative correlations (red), and relative diversity of the DAT
(blue). Diversity is a measure of the number of unique feature selection/classification
methods used. 65(c) (next page): Summary of the positive and negative correla-
tions for each end point. 65(d) (next page): Summary of the positive and negative
correlations for each performance metric.
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(c) Summary of Endpoints: Correlation of internal cross validation to external validation after swap-























(d) Summary of Performance Metrics: Correlation of internal cross validation to external validation
after swapping the training and testing data.


























Does the candidate model selected with metric A correspond
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MCC and Accuracy MCC and AUC Accuracy and AUC
(a) Concordance of candidate model selection using different performance metrics.
Figure 66: Concordance of candidate model selection using different performance
metrics. 66(a): Each cell represents a measure of model selection concordance using
one of three pairs of performance metric combinations: (MCC and Accuracy, left
column), (MCC and AUC, middle column), and (Accuracy and AUC, right column).
Classification model performance was computed using these performance metrics and
averaging 10 iterations of 5-fold cross validation. Light gray squares indicate that
there were less than three data points available. Green squares indicate that the best
model selected using metric A is the same as the best model selected using metric
B. Red indicates that the best models were not the same. Brightness of the red and
green squares indicate the significance of the comparison. A brighter square means
that there were more models to choose from. 66(b) (next page): Summary of the
percentage of model matches for each endpoint, ordered by percentage of matches
minus percentage of mismatches. 66(c) (next page): Summary of the percentage of
model matches for each performance metric comparison.
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(b) Summary of Endpoints: Concordance of candidate model selection using different performance
metrics.





















(c) Summary of Performance Metrics: Concordance of candidate model selection using different per-
formance metrics.
Figure 66 parts (b) and (c). Figure part (a) and full caption on the previous page.
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66, this is sometimes not true. This result correlates to those of a previous study
that examined several performance metrics and concluded that each metric measures
a different aspect of performance [40]. In the MAQC empirical study, we can see
that there are varying degrees of concordance between selected candidate models
depending on which performance metrics we compare. For example, there is a high
concordance between the MCC and accuracy metrics (Figure 66(a), left panel).
Comparing AUC to either MCC or accuracy, however, reveals that AUC is quite
different (Figure 66(a), middle and right panels). In fact, the AUC measures the
correctness of rank order whereas the MCC and accuracy measure only performance
of binary classification. Figure 66(c) summarizes the level of concordance between
each pair of performance metrics. MCC and accuracy agree in approximately 70% of




When building predictive models for clinical use, we often want to assess classification
performance in order to tune model parameters. Some of these model parameters
include feature size and various classifier properties. We consider only the case of
two classes, i.e., the classifier attempts to label samples as either positive or negative
depending on sample features. We assume that samples cannot simultaneously belong
to both positive and negative groups. Consequently, we can define four numbers that
describe the resulting classification. TP, the true positive count, is the number of
samples classified as positive that are actually positive. TN, the true negative count,
is the number of samples classified as negative that are actually negative. FP, the
false positive count, is the number of samples classified as positive that are actually
supposed to be negative. And FN, the false negative count, is the number of samples
classified as negative that are actually supposed to be positive. We can summarize
these four variables in the following table:
Table 26: Summarizing the performance of a prediction rule.
Actual Positives (AP) Actual Negatives (AN) Total
Predicted Positives (PP) TP FP P ′




The simplest performance metric is accuracy, which is the ratio of correctly classified
samples to the total number of samples:
Accuracy =
TP + TN
TP + TN + FP + FN
(59)
We can also represent this information as fractions of the total number of samples.
For example, the true positive fraction is the ratio of the total number of true positives





Similarly, the false positive fraction is the ratio of the total number of false positives





TPF is also known as sensitivity (Se), which is the rate at which a test correctly
identifies positive samples. In terms of disease classification, if the disease state is the
positive class, it is the rate at which a test correctly identifies diseased individuals as
such. Specificity (Sp) is the rate at which a test correctly identifies negative samples.
Again, in terms of disease classification, it is the rate at which a test correctly identifies
the disease-free individuals as such. Specificity is equivalent to 1 − FPF .
In theory, a random classifier should yield 50% accuracy. In practice, however,
training and validation data rarely have equal class sample sizes. Consequently,
the measure of classification accuracy may be misleading. For example, assume we
have 80 positive samples and 20 negative samples with sensitivity (TPF) and speci-
ficity (1-FPF) fixed at 0.75 and 0.0, respectively. Accuracy for this case would be
(0.75*80+0.0*20)/(80+20)=0.6. However, if we have 50 positive samples and 50 neg-
ative samples, then the accuracy would be (0.75*50+0.0*50)/(50+50)=0.375. Thus,
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accuracy is dependent on prevalence. We can show this more generally by defining N+
and N- as the number of positive and negative samples, respectively, and computing
the accuracy as
Accuracy =
Se · N+ + Sp · N−
N+ + N−
. (62)





then we may also represent accuracy as
Accuracy = Se · P + Sp · (1 − P ), (64)
indicating that accuracy is a weighted average of sensitivity and specificity. We can
directly observe the effect of prevalence on accuracy by plotting accuracy as a function
of TPF , FPF , and P :
Accruacy = FAcc(TPF, FPF, P ) = TPF · P + (1 − FPF ) · (1 − P ). (65)
For each value of P , accuracy is a plane that tilts on the TPF = 1 − FPF = Acc
line (Figure 67). Accuracy values for fixed TPF and FPF vary significantly when
TPF and FPF are either both large or both small. We can explain this in another
way by observing that when either sensitivity or specificity is close to zero, accuracy
heavily depends on prevalence.
D.2 Area Under the ROC Curve (AUC)
While accuracy measures the performance of a classifier using a single threshold,
the receiver/operating characteristic (ROC) curve captures the performance at all
possible thresholds. For example, most classifiers will assign continuous numeric
values to each sample, which are then used to make class assignments based on
threshold. For a particular threshold, we can compute the TPF and FPF values.
By varying the threshold, we can observe multiple TPF and FPF pairs. These
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Figure 67: Accuracy as a function of TPF, FPF, and Prevalence. Each surface
corresponds to a different prevalence ratio.
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pairs trace a curve that ranges from TPF = FPF = 0 to TPF = FPF = 1. If
all thresholds are perfect (i.e., FP = 0 and FN = 0 for all thresholds), then the
ROC curve rises along the vertical line FPF = 0 and runs along the horizontal line
TPF = 1. If the classifier performs no better than random chance, the ROC curve
runs along the line FPF = TPF . Thus, we can measure the overall performance of
the classifier at all possible thresholds by integrating the area under the ROC curve,























where xi and yj are continuous classifier outputs for positive and negative samples,
respectively. Note that in the case of ties, the summation is weighted by 0.5.
If a classifier returns only binary values, AUC reduces to the expected value at
a single pair of TPF and FPF . The binary AUC is the average of sensitivity and
specificity
AUCbin = FAUC(TPF, FPF ) =
1
2
(Se + Sp) =
1
2
(TPF − FPF + 1), (67)
which is similar to the expression for accuracy except it is independent of prevalence,
P .
D.3 Matthews Correlation Coefficient (MCC)
Although AUC is attractive because of its invariance to prevalence, it measures the
performance of a classifier at all thresholds, most of which may not be relevant to
the problem at hand. The Matthews Correlation Coefficient (MCC) attempts to find
a compromise between accuracy and AUC. The formula for MCC is a non-linear
function of TP , TN , FP , and FN :
MCC = FMCC(TPF, FPF, P ) (68)
=
TP · TN − FP · FN
√

















Figure 68: MCC as a function of TPF, FPF, and Prevalence. Each prevalence
corresponds to a different prevalence ratio.
In Figure 68, we can see that as prevalence changes, the MCC surfaces still change,
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